WO2015108029A1 - ヒアルロン酸および/またはその塩およびその製造方法、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 - Google Patents
ヒアルロン酸および/またはその塩およびその製造方法、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 Download PDFInfo
- Publication number
- WO2015108029A1 WO2015108029A1 PCT/JP2015/050638 JP2015050638W WO2015108029A1 WO 2015108029 A1 WO2015108029 A1 WO 2015108029A1 JP 2015050638 W JP2015050638 W JP 2015050638W WO 2015108029 A1 WO2015108029 A1 WO 2015108029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- salt
- mass
- raw material
- acid
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 545
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 539
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 537
- 150000003839 salts Chemical class 0.000 title claims abstract description 254
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 235000013305 food Nutrition 0.000 title claims description 22
- 239000002537 cosmetic Substances 0.000 title claims description 20
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 45
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000460 chlorine Substances 0.000 claims abstract description 29
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 29
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000011593 sulfur Substances 0.000 claims abstract description 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 208
- 239000002994 raw material Substances 0.000 claims description 170
- 239000000243 solution Substances 0.000 claims description 101
- 230000002378 acidificating effect Effects 0.000 claims description 85
- 239000007788 liquid Substances 0.000 claims description 55
- 239000003957 anion exchange resin Substances 0.000 claims description 43
- 238000001694 spray drying Methods 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 38
- 239000002245 particle Substances 0.000 claims description 34
- 238000004108 freeze drying Methods 0.000 claims description 31
- 239000011347 resin Substances 0.000 claims description 24
- 229920005989 resin Polymers 0.000 claims description 24
- 239000003929 acidic solution Substances 0.000 claims description 16
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 110
- 238000000354 decomposition reaction Methods 0.000 description 85
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- 238000003756 stirring Methods 0.000 description 48
- 239000007790 solid phase Substances 0.000 description 41
- 239000007791 liquid phase Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 36
- 239000007858 starting material Substances 0.000 description 34
- 239000000843 powder Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 239000007787 solid Substances 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 28
- -1 hyaluronic acid salt Chemical class 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 150000002772 monosaccharides Chemical class 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 238000010908 decantation Methods 0.000 description 13
- 150000004044 tetrasaccharides Chemical class 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000007921 spray Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 150000008163 sugars Chemical group 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000013324 preserved food Nutrition 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229940092738 beeswax Drugs 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000013611 frozen food Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical class COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- FCWRAGWRNLDKBB-UQIIZPHYSA-N N[C@@H](CCC(=O)OC(CCCCCCCCCCC)=O)C(=O)OC(CCCCCCCCCCC)=O.[Na] Chemical compound N[C@@H](CCC(=O)OC(CCCCCCCCCCC)=O)C(=O)OC(CCCCCCCCCCC)=O.[Na] FCWRAGWRNLDKBB-UQIIZPHYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002387 Phytoglycogen Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011367 bulky particle Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 238000000237 capillary viscometry Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920006319 cationized starch Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000009841 combustion method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940062933 dimethylsilanol hyaluronate Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000013944 peach juice Nutrition 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Definitions
- the present invention relates to hyaluronic acid and / or a salt thereof and a production method thereof, and a food, a cosmetic and a pharmaceutical containing the hyaluronic acid and / or a salt thereof.
- Hyaluronic acid is widely distributed in living tissues such as chicken crown, umbilical cord, skin, cartilage, vitreous body, and joint fluid, and is widely used as a component of cosmetics, pharmaceuticals, and foods, for example.
- hyaluronic acid is used as a component of cosmetics, pharmaceuticals, and foods, handling properties such as tableting suitability at the time of formulation are required.
- Patent Documents 1 and 2 purification of hyaluronic acid is usually performed by precipitation by adding ethanol or freeze-drying.
- hyaluronic acid when purified by lyophilization, solid (eg, cotton-like) hyaluronic acid having a low density is usually obtained.
- Hyaluronic acid having such a low density may have poor tableting suitability when formulated.
- the present invention provides hyaluronic acid and / or a salt thereof excellent in handleability such as tableting suitability and a production method thereof, and foods, cosmetics and pharmaceuticals containing the hyaluronic acid and / or a salt thereof.
- hyaluronic acid and / or a salt thereof having a predetermined molecular weight and bulk density have excellent characteristics (for example, handleability).
- the hyaluronic acid and / or salt thereof has an average molecular weight of 3,500 or less, a ratio of disaccharides of 1% by mass to 30% by mass, and a chlorine content and a sulfur content. 1% by mass or less and the bulk density is larger than 0.25 g / cm 3 .
- the average particle size may be 10 ⁇ m or more and 35 ⁇ m or less.
- the standard deviation of the particle diameter can be 0.1 or more and 0.3 or less.
- the method for producing hyaluronic acid and / or a salt thereof according to one embodiment of the present invention includes an acid comprising a lower alcohol, a raw material hyaluronic acid having an average molecular weight of 3,500 to 100,000, and / or a salt thereof, and an acid.
- Preparing a raw material hyaluronic acid solution Acid hydrolyzing the raw material hyaluronic acid and / or salt thereof in the acidic raw material hyaluronic acid solution obtained in the preparing step; Treating an acidic solution containing the hydrolyzate obtained by the acid hydrolysis with an anion exchange resin; Spray-drying or freeze-drying the resin-treated hydrolyzate,
- the acidic raw material hyaluronic acid solution contains 15% by mass or more and 35% by mass or less of the raw material hyaluronic acid and / or a salt thereof, and
- the acidic raw material hyaluronic acid solution contains 5 parts by mass or more and 60 parts by mass or less of the lower alcohol with respect to 100 parts by mass of the raw material hyaluronic acid and / or a salt thereof.
- step of spray drying includes the step of spray drying the liquid containing the hydrolyzate, and the mass relative to the mass of the liquid containing the hydrolyzate.
- the mass of the hydrolyzate can be 8% by mass or more and 35% by mass or less.
- the foodstuff which concerns on 1 aspect of this invention contains the hyaluronic acid and / or its salt in any one of said 1 thru
- a cosmetic according to one embodiment of the present invention includes the hyaluronic acid and / or salt thereof described in any one of 1 to 3 above.
- a pharmaceutical product according to one aspect of the present invention includes the hyaluronic acid and / or salt thereof described in any one of 1 to 3 above.
- the hyaluronic acid and / or salt thereof according to any one of 1 to 3 above has an average molecular weight of 3,500 or less, a disaccharide ratio of 1% by mass to 30% by mass, a chlorine content and a sulfur content Are 1% by mass or less and the bulk density is higher than 0.25 g / cm 3 , the handleability such as tableting suitability is excellent.
- the hyaluronic acid and / or a salt thereof can be used, for example, as a component of foods, cosmetics and pharmaceuticals.
- the method for producing hyaluronic acid and / or a salt thereof according to 4 or 5 described above comprises: lower alcohol; raw hyaluronic acid and / or salt thereof having an average molecular weight of 3,500 or more and 100,000 or less; and an acid.
- the average molecular weight is 3,500 or less
- the proportion of disaccharides is 1% by weight or more.
- hyaluronic acid and / or a salt thereof having a chlorine content of 30% by mass or less, a chlorine content and a sulfur content of 1% by mass or less, and a bulk density of more than 0.25 g / cm 3. it can.
- parts means “parts by mass” and “%” means “mass%” unless otherwise specified.
- the hyaluronic acid and / or salt thereof has an average molecular weight of 3,500 or less, a disaccharide ratio of 1% by mass to 30% by mass, and any chlorine content and sulfur content. Is 1% by mass or less, and the bulk density is larger than 0.25 g / cm 3 .
- hyaluronic acid refers to a polysaccharide having one or more repeating structural units composed of disaccharides of glucuronic acid and N-acetylglucosamine.
- the “hyaluronic acid salt” is not particularly limited, but is preferably a food or pharmaceutically acceptable salt, for example, sodium salt, potassium salt, calcium salt, zinc salt, magnesium salt, ammonium salt, etc. Is mentioned.
- Hyaluronic acid is basically a disaccharide or more containing at least one disaccharide unit in which the 1-position of ⁇ -D-glucuronic acid and the 3-position of ⁇ -DN-acetyl-glucosamine are bonded, and ⁇ It is basically composed of -D-glucuronic acid and ⁇ -DN-acetyl-glucosamine, and has one or more disaccharide units linked.
- the hyaluronic acid and / or salt thereof according to the present embodiment is substantially free of non-reducing terminal sugars (for example, those having unsaturated carbons at positions 4 and 5 of glucuronic acid) (that is, non-reducing terminal sugars).
- the content can be 1% by mass or less).
- disaccharide means one disaccharide unit (two saccharides) in which the 1-position of ⁇ -D-glucuronic acid and the 3-position of ⁇ -DN-acetyl-glucosamine are combined.
- Tetrasaccharide means two disaccharide units (consisting of four sugars), and “hexaccharide” means the disaccharide. Three units (composed of 6 sugars) are referred to, and “octasaccharide” refers to 4 disaccharide units (composed of 8 sugars).
- all of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide are those containing no non-reducing terminal sugar (saturated sugar).
- “bulk density” is a value measured according to the method described in “16th revised Japanese pharmacopoeia, 3. Powder physical property measurement method, 3.01 bulk density and tap density measurement method”. is there.
- the hyaluronic acid and / or salt thereof according to this embodiment has an average molecular weight of 3,500 or less and a bulk density of greater than 0.25 g / cm 3 , so that it is suitable for tableting while having a low molecular weight. (Handling ability) such as (tableting accuracy) is excellent.
- the hyaluronic acid and / or salt thereof according to the present embodiment has an average molecular weight of 3,500 or less and preferably 2,500 or less in that the purity can be further increased. It is preferable that it is 1,000 or more.
- the average molecular weight of hyaluronic acid and / or a salt thereof can be measured by a method using HPLC described later.
- a value obtained by multiplying the peak area by the molecular weight of each peak of hyaluronic acid and / or its salt obtained by each HPLC measurement is calculated.
- the calculated values are integrated.
- the average molecular weight can be calculated by dividing the integrated value by the total peak area.
- the hyaluronic acid and / or salt thereof according to this embodiment can have a purity of 90% or more, preferably 95% or more, and more preferably 98% or more.
- purity refers to the ratio of the hyaluronic acid and / or salt thereof according to the present embodiment excluding components other than hyaluronic acid and / or salt thereof.
- components other than hyaluronic acid and / or a salt thereof include monosaccharides (eg, glucuronic acid, N-acetylglucosamine, and monosaccharides derived therefrom), and non-reducing terminal sugars.
- the purity of hyaluronic acid and / or a salt thereof according to the present embodiment can be calculated by, for example, removing a peak corresponding to a monosaccharide from HPLC spectrum data of hyaluronic acid and / or a salt thereof.
- the proportion of monosaccharide is usually 3% by mass or less, and preferably 2% by mass or less.
- the hyaluronic acid and / or salt thereof according to this embodiment may have a b value (hereinafter also simply referred to as “b value”) representing a hue of a color of 10 or less, preferably 8 or less. More preferably, it is usually 0 or more.
- B value is a value that defines the hue (hue) of the color of the substance. The larger the b value, the stronger the yellowness, while the smaller the b value, the stronger the blueness.
- the low molecular weight hyaluronic acid and / or salt thereof of the present invention has an L value (hereinafter also referred to simply as “L value”) representing the lightness of the color of 90 or more, more preferably an L value of 92 or more, More preferably, the L value is 93 or more.
- L value representing the lightness of the color of 90 or more, more preferably an L value of 92 or more, More preferably, the L value is 93 or more.
- the L value is a value that defines the lightness of the color of the substance, and is represented by a numerical value between 0 and 100.
- An L value of 100 indicates the brightest state (perfect white), while an L value of 0 indicates the darkest state (perfect black).
- B value and L value can be displayed in Lab chromaticity coordinates by the color difference display method defined by JIS Z 8730-1995. Moreover, b value and L value can be measured with a commercially available color difference meter. In the present invention, the b value and L value are measured for solid low-molecular hyaluronic acid and / or a salt thereof.
- the b value and L value of hyaluronic acid and / or a salt thereof according to the present embodiment are obtained by, for example, using a 10 ⁇ lens on a color difference meter (trade name “COLOR AND COLOR DIFFERENCE METER MODEL 1001 DP”, manufactured by Nippon Denshoku Industries Co., Ltd.). It is possible to measure by mounting 1 g or more of a measurement sample on a glass cell.
- the b value representing the hue of the color measured by a color difference meter is 10 or less (and the L value is 90 or more), so that high whiteness is achieved.
- it can be used as a raw material for cosmetics, foods, and pharmaceuticals.
- the chlorine content and the sulfur content are both 1% by mass or less, so that tableting suitability is excellent.
- the metal shape of chlorine such as sodium chloride or the metal salt of sulfide such as sodium sulfate increases, resulting in nonuniform particle shape. It is presumed that the property will increase and the binding force during tableting will be weakened.
- the hyaluronic acid and / or salt thereof according to this embodiment has a chlorine content and a sulfur content of 1% by mass or less, and a low chlorine content and a low sulfur content. Since the binding property is increased and the binding force at the time of tableting is increased, the tableting suitability is improved.
- the hyaluronic acid and / or salt thereof according to the present embodiment is used for foods, pharmaceuticals, and cosmetics as described later.
- salts such as sodium chloride may impair the stability of the system. Especially in an emulsifying system, it can be a factor of demulsification.
- halides such as sodium chloride
- sulfides such as sodium sulfate
- acids such as hydrochloric acid and sulfuric acid. It is desired that chlorine and sulfur to be reduced are reduced as much as possible.
- the hyaluronic acid and / or salt thereof according to this embodiment has a high bulk density, and the chlorine content can be 1% by mass or less from the viewpoint of improving the emulsion stability and safety.
- the content is preferably 0.8% by mass or less, and more preferably 0.5% by mass or less.
- the chlorine content and sulfur content of the hyaluronic acid and / or salt thereof according to the present embodiment are determined by a known method (for example, elemental analysis (combustion method, ICP emission spectroscopic method, atomic absorption method, fluorescent X-ray analysis method). ), Mass spectrometry). Furthermore, in the present invention, the chlorine content of hyaluronic acid and / or a salt thereof according to the present embodiment can be measured by calculating from the value measured by the Mole method.
- the hyaluronic acid and / or salt thereof according to this embodiment can have an average particle size of 10 ⁇ m or more and 35 ⁇ m or less, preferably 15 ⁇ m or more, and preferably 30 ⁇ m or less, in terms of superior tableting suitability. It is preferable that
- the standard deviation of the particle size is an index indicating the variation in the particle size of the hyaluronic acid and / or salt thereof according to the present embodiment. Since the hyaluronic acid and / or salt thereof according to the present embodiment has little variation in particle diameter, the standard deviation of the particle diameter is 0 in that tableting suitability can be further improved by increasing the density. .1 or more and 0.3 or less, preferably 0.15 or more, and preferably 0.25 or less.
- the hyaluronic acid and / or salt thereof according to the present embodiment has a disaccharide ratio of 1% by mass or more and 30% by mass or less, and 5% by mass or more in that the physiological function inherent to hyaluronic acid can be exhibited.
- it is 8% by mass or more, on the other hand, it is preferably 25% by mass or less, and more preferably 20% by mass or less.
- hyaluronic acid-degrading enzyme hyaluronic acid-degrading enzyme
- disaccharide saturated disaccharide
- hyaluronic acid and / or a salt thereof according to this embodiment containing a disaccharide can be obtained by using the production method described later.
- the hyaluronic acid and / or salt thereof according to this embodiment contains a predetermined amount of a short sugar chain sugar because the ratio of disaccharide is 1% by mass or more and 30% by mass or less. Thereby, since hygroscopicity becomes high and binding power increases, the hyaluronic acid and / or salt thereof according to the present embodiment can be obtained as bulky particles. Moreover, the hyaluronic acid and / or salt thereof according to this embodiment may have a monosaccharide ratio of 1.5 mass% or more and 3 mass% or less.
- the hyaluronic acid and / or salt thereof according to this embodiment can contain no hyaluronic acid-degrading enzyme in that antigenicity can be further reduced.
- “not containing hyaluronic acid-degrading enzyme” means that the content of hyaluronic acid-degrading enzyme in the hyaluronic acid and / or salt thereof according to this embodiment is 1% by mass or less.
- the hyaluronic acid and / or salt thereof according to this embodiment is obtained by acid decomposition (for example, the production method according to this embodiment described later), and acid-decomposed hyaluronic acid and / Or a salt thereof, and more specifically, an acid-decomposed hyaluronic acid and / or a salt thereof obtained by acid decomposition in any of the production methods is more preferable.
- the hyaluronic acid decomposing enzyme may remain in the reduced molecular weight hyaluronic acid and / or the salt thereof.
- the hyaluronic acid and / or salt thereof according to this embodiment obtained without using hyaluronic acid-degrading enzyme by the production method according to the embodiment described later does not contain hyaluronic acid-degrading enzyme. Antigenicity is further reduced.
- the hyaluronic acid and / or salt thereof according to this embodiment can have a ratio of octasaccharide of 1% by mass or more and 30% by mass or less in terms of more reliably exerting physiological activity derived from octasaccharide. More preferably, it is at least mass%.
- the total of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide can be 5% by mass or more and 80% by mass or less, and can be 10% by mass or more. On the other hand, it is preferable that it is 70 mass% or less.
- the hyaluronic acid and / or salt thereof has an average molecular weight of 3,500 or less, and the total of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide is 5% by mass or more and 80%. It can be not more than mass%, and can be not less than 20 mass% and not more than 60 mass%. In this case, the ratio of disaccharide can be 1% by mass or more and 30% by mass or less. In this case, the ratio of octasaccharide can be 1% by mass or more and 30% by mass or less.
- the ratio (mass%) of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide in hyaluronic acid and / or its salt can be identified by HPLC for hyaluronic acid and / or its salt. More specifically, by dividing the peak area of each peak of hyaluronic acid and / or its salt (for example, molecular weight 400 for disaccharides) obtained by each HPLC measurement by the total peak area, hyaluronic acid and The ratio (mass%) of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide in / or its salt can be calculated.
- the kinematic viscosity of a 5% by mass aqueous solution of the hyaluronic acid and / or salt thereof is 2.0 mm 2 / s or less (preferably 1.5 mm 2 / s or less, More preferably, it can be 1.3 mm 2 / s or less.
- the kinematic viscosity of a 5% by mass aqueous solution of hyaluronic acid and / or a salt thereof can be measured using an Ubbelohde viscometer (manufactured by Shibata Kagaku Kikai Kogyo Co., Ltd.). At this time, an Ubbelohde viscometer having a coefficient such that the number of seconds of flow is 200 to 1000 seconds is selected. The measurement is performed in a constant temperature water bath at 30 ° C. so that there is no temperature change.
- the kinematic viscosity (unit: mm 2 / s) can be obtained from the product of the number of seconds of flow of the aqueous solution measured by the Ubbelohde viscometer and the coefficient of the Ubbelohde viscometer.
- the average molecular weight is 3,500 or less
- the proportion of disaccharides is 1% by mass or more and 30% by mass or less
- the chlorine content and the sulfur content are both When it is 1% by mass or less and the bulk density is larger than 0.25 g / cm 3 , it is excellent in handling properties such as tableting aptitude.
- a method for producing hyaluronic acid and / or salt thereof includes a lower alcohol and an average molecular weight of 3,500 to 100,000.
- the acid solution of the salt hereinafter also referred to as “liquid phase decomposition step”
- an acidic solution containing the hydrolyzate obtained by the acid hydrolysis are treated with an anion exchange resin.
- anion exchange resin treatment step also referred to as “anion exchange resin treatment step”
- spray-drying spray-drying (spray-dr) the hydrolyzate treated with the resin.
- freeze drying process or freeze drying process
- the acidic raw material hyaluronic acid solution is 15% by mass or more and 35% by mass
- the following raw material hyaluronic acid and / or salt thereof, and the acidic raw material hyaluronic acid solution is 5 parts by mass or more and 60 parts by mass or less with respect to 100 parts by mass of the raw material hyaluronic acid and / or salt thereof.
- Step of preparing an acidic raw material hyaluronic acid solution In the step of preparing the acidic raw material hyaluronic acid solution, an acidic raw material hyaluronic acid solution containing a lower alcohol, a raw material hyaluronic acid having an average molecular weight of 3,500 to 100,000, and / or a salt thereof, and an acid is prepared.
- hyaluronic acid and / or a salt thereof having a molecular weight of 3,500 or less and high whiteness can be obtained.
- the molecular weight of the salt is preferably 5,000 or more, more preferably 6,000 or more, and preferably 8,000 or more, on the other hand, preferably 50,000 or less, and 20,000 or less. It is more preferable that
- the average molecular weight of the raw material hyaluronic acid and / or salt thereof can be measured by the following method. That is, about 0.05 g of hyaluronic acid (this product) was accurately weighed and dissolved in a 0.2 mol / L sodium chloride solution to make exactly 100 mL, and 8 mL, 12 mL and 16 mL of this solution were accurately weighed.
- a solution obtained by adding a 0.2 mol / L sodium chloride solution to each to make exactly 20 mL is used as a sample solution.
- This sample solution and a 0.2 mol / L sodium chloride solution were 30.0 ⁇ 0.1 ° C. according to the viscosity measurement method (first method capillary viscometry method) of the Japanese Pharmacopoeia (16th revision) general test method.
- the specific viscosity is measured by (Equation (A)), and the reduced viscosity at each concentration is calculated (Equation (B)).
- a graph is drawn with the reduced viscosity on the vertical axis and the concentration (g / 100 mL) of the product converted to dry matter on the horizontal axis, and the intrinsic viscosity is determined from the intersection of the straight line connecting the points and the vertical axis.
- the intrinsic viscosity obtained here is substituted into Laurent's formula (formula (C)), and the average molecular weight is calculated (Torvar C Laurent, Marion Ryan, and Adolph Pietroszkiewicz, "Fractionation of hyaluronic Acid", Biochemistry Aci.
- the liquid phase decomposition step while preventing browning of the raw material hyaluronic acid and / or its salt, and lowering the molecular weight of the raw material hyaluronic acid and / or its salt (for example, the resulting hyaluronic acid and / or its salt)
- the average molecular weight of the salt can be 3,500 or less), and the generation of monosaccharides can be suppressed, and the concentration of the raw material hyaluronic acid and / or salt in the acidic raw material hyaluronic acid solution (the acidic The mass of the raw material hyaluronic acid and / or a salt thereof with respect to the mass of the raw material hyaluronic acid solution is 15% by mass or more, preferably 16% by mass or more, more preferably 18% by mass or more, It is 35 mass% or less, and it is preferable that it is 32 mass% or less.
- the solvent used in the acidic raw material hyaluronic acid solution is preferably a hydrous solvent (preferably water) from the viewpoint of excellent solubility of the raw material hyaluronic acid and / or its salt. If the salt can be dissolved, the solvent may be water or a hydrous solvent containing 30% by mass or less of an organic solvent miscible with water.
- lower alcohol means an alcohol having 1, 2 or 3 carbon atoms, and examples thereof include methanol, ethanol, 1-propanol, and 2-propanol. Among these, 1 type (s) or 2 or more types can be used as a lower alcohol.
- the lower alcohol for example, methanol and / or ethanol are preferable, and ethanol is more preferable.
- the acidic raw material hyaluronic acid solution is based on 100 parts by weight of the raw material hyaluronic acid and / or salt thereof in that the molecular weight of the finally obtained hyaluronic acid and / or salt thereof can be more reliably adjusted to 3,500 or less.
- the lower alcohol is preferably contained in an amount of 10 parts by mass or more or 50 parts by mass or less.
- the acid contained in the acidic raw material hyaluronic acid solution any acid can be used as long as it can adjust the pH of the acidic raw material hyaluronic acid solution to be acidic.
- the acid may be, for example, an inorganic acid such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, phosphoric acid, acetic acid, citric acid, a sulfone group-containing organic acid (for example, p-toluenesulfonic acid).
- Trifluoromethanesulfonic acid Trifluoromethanesulfonic acid
- organic acids such as fluorine atom-containing organic acids (for example, trifluoroacetic acid) can be used.
- the acidic raw material hyaluronic acid solution In the step of preparing the acidic raw material hyaluronic acid solution, a mixture of the lower alcohol and the raw material hyaluronic acid and / or a salt thereof (here, the mixture is added to 100 parts by weight of the raw material hyaluronic acid and / or a salt thereof).
- the acidic raw material hyaluronic acid solution can be prepared by adding 5 parts by mass or more and 60 parts by mass or less of the lower alcohol) to an acid-containing liquid (acidic liquid).
- the acidic raw material hyaluronic acid solution can be prepared by adding an acid to a solution containing the raw material hyaluronic acid and / or a salt thereof and a lower alcohol.
- the raw material hyaluronic acid and / or a salt thereof can be moisted with a lower alcohol in the mixture.
- the acidic raw material hyaluronic acid solution may be prepared by adjusting the lower alcohol used in the solid-phase decomposition step to a desired ratio.
- the raw material hyaluronic acid and / or salt thereof is wetted with the lower alcohol means that at least a part of the raw material hyaluronic acid and / or salt thereof is present as a solid in the lower alcohol, A state in which an acid and / or a salt thereof is wet and swollen by a lower alcohol.
- the raw material hyaluronic acid and / or a salt thereof is wetted with a lower alcohol
- a mixture of the raw material hyaluronic acid and / or a salt thereof and a lower alcohol is added to the acidic liquid, and the acidic raw material hyaluronic acid is added.
- the raw material hyaluronic acid and / or salt thereof becomes lumped in the acidic liquid (that is, the raw material hyaluronic acid and / or salt thereof aggregates in the acidic liquid, Not uniformly dispersed) and the dispersibility of the raw material hyaluronic acid and / or salt thereof in an acidic solution can be improved.
- the added to the mass of the acidic liquid before adding the mixture is 100 parts by mass in terms of facilitating the progress of lowering the molecular weight
- the mass of the mixture (the mass of the mixture / the mass of the acidic liquid before adding the mixture) is preferably 10 parts by mass or more and 40 parts by mass or less, more preferably 20 parts by mass or more, More preferably, it is 30 parts by mass or less.
- the pH of the acidic raw material hyaluronic acid solution is such that browning of the raw material hyaluronic acid and / or salt thereof can be prevented and the molecular weight of the raw material hyaluronic acid and / or salt thereof can be reduced.
- 0.2 or more, preferably 0.3 or more, more preferably 0.5 or more, still more preferably 0.8 or more, while 1.8 or less Preferably, it is 1.5 or less, more preferably 1.0 or less.
- the raw material hyaluronic acid having an average molecular weight of 3,500 or more and 100,000 or less and / or a salt thereof is contained in an acidic raw material hyaluronic acid solution containing 15% by mass or more and 35% by mass or less. Holding, the raw material hyaluronic acid and / or its salt is hydrolyzed. As a result, the raw material hyaluronic acid and / or salt thereof is reduced in molecular weight by acid hydrolysis, and a hydrolyzate (hyaluronic acid and / or salt thereof) having a lower molecular weight is obtained.
- the temperature of the reaction solution is preferably 85 ° C. or lower (preferably 80 ° C. or lower), from the viewpoint of preventing browning of hyaluronic acid and / or a salt thereof reduced in molecular weight, More preferably, it is 60 ° C. or higher (preferably 65 ° C. or higher).
- reaction time In the liquid phase decomposition step, the reaction time is usually preferably 30 minutes or longer and 10 hours or shorter, preferably 60 minutes or longer and 8 hours or shorter from the viewpoint that browning of the low molecular weight hyaluronic acid and / or salt thereof can be prevented. It is more preferable that
- Hyaluronic acid having an average molecular weight of 3,500 or less (preferably 2,800 or less, more preferably 2,500 or less, on the other hand, preferably 1,000 or more, more preferably 1,200 or more) and a liquid phase decomposition step; / Or its salt can be obtained.
- an acidic solution containing the hydrolyzate obtained by the acid hydrolysis is treated with an anion exchange resin.
- the hydrolyzate is hyaluronic acid and / or a salt thereof having a molecular weight smaller than that of the raw material hyaluronic acid and / or a salt thereof obtained by reducing the molecular weight of the raw material hyaluronic acid and / or a salt thereof.
- anions in the acidic solution for example, halide ions such as chloride ions, bromide ions, fluoride ions and iodide ions, and sulfide ions such as sulfate ions
- anions in the acidic solution for example, halide ions such as chloride ions, bromide ions, fluoride ions and iodide ions, and sulfide ions such as sulfate ions
- elements for example, chlorine and sulfur
- the acidic solution containing the hydrolyzate obtained in the liquid phase decomposition step is treated with the anion exchange resin after the liquid phase decomposition step, so that the treatment efficiency is excellent.
- the anion exchange resin to be used include strongly basic, weakly basic, and gel-type and porous-type ion exchange resins.
- alkali may be added to the acidic solution to increase the pH of the acidic solution (less than pH 7), and then the acidic solution may be treated with an anion exchange resin. .
- an anion exchange resin may be added to the acidic solution after the holding (acid hydrolysis) and stirred.
- an anion exchange resin is fixed in a container, and the acidic solution is placed in the container and stirred to bring the hyaluronic acid and / or salt thereof in the acidic solution into contact with the anion exchange resin.
- an anion for example, the anion illustrated above
- the anion exchange resin and the acidic solution can be easily separated after the treatment.
- the acidic solution after the holding (acid hydrolysis) may be passed through a column filled with an anion exchange resin.
- the pH of the liquid obtained in the liquid phase decomposition step for example, anion exchange resin treatment step
- spray drying or freeze drying may be performed.
- the pH of the liquid is 4 or more and 8 or less (preferably 5 or more, preferably 7 or more in that it can prevent browning of the finally obtained hyaluronic acid and / or salt thereof and can improve the stability. It is preferable to adjust to the following.
- the pH can be adjusted with basic substances (for example, hydroxides of alkali metals or alkaline earth metals such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, carbonate Basic inorganic salts such as alkali metal or alkaline earth metal carbonate such as magnesium, alkali metal such as sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate or bicarbonate of alkaline earth metal, or Basic organic salts).
- basic substances for example, hydroxides of alkali metals or alkaline earth metals such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, carbonate
- Basic inorganic salts such as alkali metal or alkaline earth metal carbonate such as magnesium, alkali metal such as sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate or bicarbonate of alkaline earth metal, or Basic organic
- the manufacturing method according to the present embodiment includes a step of spray drying or freeze drying the hydrolyzate subjected to the resin treatment (treatment with an anion exchange resin) after the anion exchange resin treatment step.
- the liquid containing the hydrolyzate is spray dried to obtain a method for producing solid hyaluronic acid and / or a salt thereof. That is, according to the spray drying step, the molecular weight is 3,500 or less, the proportion of disaccharides is 1% by mass or more and 30% by mass or less, the chlorine content and the sulfur content are both 1% by mass or less, and Hyaluronic acid and / or a salt thereof having a bulk density greater than 0.25 g / cm 3 can be obtained.
- the hyaluronic acid and / or salt thereof according to the above embodiment can be obtained by the spray drying process.
- the spray-drying step the final solution of hyaluronic acid and / or its salt is obtained by spray-drying a liquid containing a hydrolyzate obtained after the liquid phase decomposition step and the anion exchange resin treatment step. It is possible to obtain hyaluronic acid and / or particles thereof that can reduce the anion content and are bulky and have little variation.
- the liquid to be spray-dried preferably contains 8% by mass or more and 35% by mass or less of the hydrolyzate in that spraying can be appropriately performed. More preferably, it is more preferably 11% by mass or more, on the other hand, it is preferably 30% by mass or less, more preferably 28% by mass or less, further preferably 26% by mass or less, more preferably 24% by mass. It is particularly preferable to include the following.
- the amount of the hydrolyzate contained in the liquid to be spray dried is the content of the raw material hyaluronic acid and / or its salt contained in the acidic raw material hyaluronic acid solution in the liquid phase decomposition step. It is a value calculated as a quantity.
- Spray dryer In the spray drying step, spray drying can be performed using a commercially available spray drying apparatus.
- Commercially available spray dryers include disk type spray dryers and vane type spray dryers.
- the heater temperature in the spray-drying step is usually 200 ° C. or lower (preferably 170 ° C. or lower), preferably 150 ° C. or higher (in terms of preventing freezing and browning of hyaluronic acid and / or a salt thereof. More preferably, it is 100 degreeC or more.
- hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or higher has a high viscosity
- a liquid containing hyaluronic acid and / or a salt thereof is usually used for appropriate spraying. It is necessary to adjust to a state where the viscosity is reduced (for example, the concentration of hyaluronic acid and / or a salt thereof is usually 1 to 8% by mass).
- the hydrolyzate since the hydrolyzate has a low viscosity, the liquid obtained in the anion exchange resin treatment step is not diluted (or in a state where the amount of dilution is small) and sprayed in the spray drying step. Can be efficient.
- the liquid to be freeze-dried preferably contains 8% by mass or more and 35% by mass or less of the hydrolyzate in that it can be appropriately frozen. More preferably, it is more preferably 11% by mass or more, more preferably 28% by mass or less, still more preferably 26% by mass or less, and particularly preferably 24% by mass or less.
- the amount of the hydrolyzate contained in the liquid to be lyophilized is the content of the raw material hyaluronic acid and / or its salt contained in the acidic raw material hyaluronic acid solution in the liquid phase decomposition step (or the liquid phase decomposition step). It is a value calculated by regarding the content of the starting material hyaluronic acid and / or its salt contained in the acidic raw material hyaluronic acid solution as the content of the hydrolyzate.
- freeze drying equipment In the freeze-drying step, freeze-drying can be performed using a commercially available freeze-drying apparatus.
- a commercially available freeze-drying apparatus includes ULVAC freeze-dryer (DFR-5N-B).
- the temperature in the freeze-drying step is usually preferably ⁇ 20 ° C. or lower (preferably ⁇ 30 ° C. or lower), and ⁇ 80 ° C. or higher (in terms of preventing browning of hyaluronic acid and / or a salt thereof) Preferably, it is more preferably ⁇ 70 ° C. or higher.
- the starting raw material hyaluronic acid having an average molecular weight of 3,000 to 500,000 is used as the second depolymerization step before the liquid phase decomposition step (first depolymerization step) and And / or a step of dispersing the salt in an acidic water-containing medium (medium) to obtain the raw material hyaluronic acid and / or a salt thereof (hereinafter also referred to as “solid phase decomposition step”).
- solid phase decomposition step an acidic water-containing medium
- the raw material hyaluronic acid and / or salt thereof is reduced in molecular weight to obtain the raw material hyaluronic acid and / or salt thereof. More specifically, in the solid phase decomposition step, at least a part of the starting raw material hyaluronic acid and / or a salt thereof is acidic hydrous by dispersing the starting raw material hyaluronic acid and / or a salt thereof in an acidic aqueous medium. The starting raw material hyaluronic acid and / or salt thereof is in a solid state without being dissolved in the medium (more specifically, the starting raw material hyaluronic acid and / or salt thereof is suspended in the acidic water-containing medium).
- the starting raw material hyaluronic acid and / or a salt thereof can be reacted with an acid in a solid state without being dissolved in an acidic water-containing medium, the molecular weight is reduced. It is possible to suppress the formation of monosaccharides by dissolving hyaluronic acid and / or a salt thereof in the reaction solution and reacting with the acid.
- the proportion of disaccharides in the hydrolyzate (hyaluronic acid and / or salt thereof) finally obtained by obtaining the subsequent liquid phase decomposition step can be adjusted to 1% by mass or more and 30% by mass or less
- the ratio of 8 sugars in the hydrolyzate (hyaluronic acid and / or salt thereof) finally obtained by obtaining the subsequent liquid phase decomposition step can be adjusted to 1% by mass or more and 30% by mass or less
- the total of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide in the hydrolyzate (hyaluronic acid and / or salt thereof) finally obtained by obtaining the subsequent liquid phase decomposition step is 5% by mass or more and 80% by mass or less. Can be adjusted.
- the starting material hyaluronic acid having an average molecular weight of 10,000 to 500,000 and / or a salt thereof was dispersed in an acidic water-containing medium to obtain hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or less.
- hyaluronic acid and / or a salt thereof having a lower molecular weight and higher water solubility are dissolved in preference to the water constituting the acidic water-containing medium, and as a result, hyaluronic acid and / or a salt thereof finally obtained Browning may occur or the amount of by-products (for example, monosaccharides) may increase (for example, the content of monosaccharides exceeds 3% by mass).
- the hyaluronic acid having an average molecular weight of 3,500 or less is obtained by the liquid phase decomposition step after the starting material hyaluronic acid and / or a salt thereof is reduced to some extent by the solid phase decomposition step And / or by obtaining the salt thereof, the occurrence of browning and the generation of by-products can be suppressed.
- the starting material hyaluronic acid and / or a salt thereof is a starting material for the starting material hyaluronic acid and / or a salt thereof, and has an average molecular weight larger than that of the starting material hyaluronic acid and / or a salt thereof.
- the average molecular weight of the starting hyaluronic acid and / or salt thereof is preferably 10,000 or more in that the average molecular weight of the starting hyaluronic acid and / or salt thereof can be 3,500 or more and 500,000 or less. More preferably, it is more than 10,000, while it is preferably less than 2,000,000, more preferably less than one million.
- the mass of the starting raw material hyaluronic acid and / or its salt relative to the mass of the acidic water-containing medium is 3% by mass or more and 20% by mass or less. It is preferably 3% by mass or more, and preferably 15% by mass or less.
- examples of the solvent used in the acidic water-containing medium in which the starting raw material hyaluronic acid and / or a salt thereof are dispersed include water-soluble organic solvents.
- examples of the water-soluble organic solvent include alcohol solvents such as methanol, ethanol, 1-propanol and 2-propanol (especially lower alcohols), ketone solvents such as acetone and methyl ethyl ketone, tetrahydrofuran, acetonitrile and the like. These can be used alone or in combination.
- the ratio of water to the total amount of the acidic water-containing medium is preferably 40% by volume or less, and more preferably 30% by volume or less. Preferably, it is usually 1% by volume or more.
- the pH of the acidic water-containing medium is 1 or less in that the raw material hyaluronic acid and / or its salt can be prevented from browning and the raw material hyaluronic acid and / or its salt can be reduced in molecular weight. It is preferable that it is, and it is more preferable that it is 0 or more.
- the second depolymerization step for example, enzymatic decomposition, thermal decomposition, acid decomposition in a state where the raw material hyaluronic acid and / or its salt is dissolved in the reaction solution, alkali decomposition, electron beam
- the starting hyaluronic acid and / or salt thereof can be reduced in molecular weight by at least one method selected from decomposition by irradiation and decomposition by ultrasonic waves to obtain the raw material hyaluronic acid and / or salt thereof.
- the starting material hyaluronic acid and / or salt thereof is dispersed in an acidic water-containing medium in that the ratio of monosaccharide, disaccharide and octasaccharide in the resulting hyaluronic acid and / or salt thereof can be easily controlled. And hydrolyzing the starting material hyaluronic acid and / or its salt with an acid in the solid state).
- the temperature of the reaction solution is usually 95 ° C. or lower (preferably 90 ° C. or lower), from the viewpoint that browning of the low molecular weight hyaluronic acid and / or salt thereof can be prevented. More preferably, it is 55 ° C. or higher (preferably 60 ° C. or higher).
- reaction time In the solid phase decomposition step, the reaction time is usually preferably 30 minutes or longer and 10 hours or shorter, preferably 60 minutes or longer and 2 hours or shorter from the viewpoint that browning of the low molecular weight hyaluronic acid and / or salt thereof can be prevented. It is more preferable that
- the liquid phase decomposition step, the anion exchange resin treatment step, and the spray drying step or the freeze drying step are obtained in the anion exchange resin treatment step. Since the spray drying step or the freeze drying step can be performed using a liquid, the hyaluronic acid and / or salt thereof according to the above embodiment can be efficiently obtained as a solid.
- a liquid containing high concentration (for example, 8% by mass to 35% by mass) of hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or less is sprayed.
- hyaluronic acid and / or a salt thereof having a high bulk density can be obtained.
- hyaluronic acid having an average molecular weight of 3,500 or less, a high bulk density (0.25 g / cm 3 or more), and a small variation in particle diameter through a spray drying process.
- the reason why the salt can be obtained is that the hyaluronic acid having an average molecular weight of 3,500 or less and / or the salt thereof is low in viscosity, and thus the concentration during spray drying can be increased. Can be sprayed smoothly.
- High molecular weight hyaluronic acid and / or salts thereof have high viscosity, In order to reduce the viscosity, the concentration must be lowered. However, when spray drying is performed using a liquid having such a low concentration, there may be a problem that hyaluronic acid cannot be recovered as a solid.
- the present inventors set the concentration in the liquid to be spray-dried to 8 mass% or more and 35 mass% or less for hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or less.
- the inventors discovered a new finding that spray drying can be performed, and created a manufacturing method according to the present embodiment.
- hyaluronic acid and / or a salt thereof according to the above embodiment can be obtained by the production method according to this embodiment.
- the manufacturing method according to the present embodiment has the following features (1) to (5).
- the production method according to this embodiment has a small amount of impurities (for example, chloride ions).
- impurities for example, chloride ions.
- Hyaluronic acid and / or its salt can be obtained, and the yield of hyaluronic acid and / or its salt is excellent.
- Raw material hyaluronic acid having an average molecular weight exceeding 100,000 and / or a salt thereof is reduced in the state of being dissolved in an acidic or alkaline raw material hyaluronic acid solution, and hyaluronic acid having an average molecular weight of 3,500 or less and / or
- hyaluronic acid and / or a salt thereof having a high whiteness and a low content of by-products (for example, monosaccharides) compared to a method for obtaining the salt thereof.
- a method of dispersing raw material hyaluronic acid and / or a salt thereof having an average molecular weight exceeding 100,000 in an acidic water-containing medium in a solid state (where the raw material hyaluronic acid and / or a salt thereof is dissolved in the acidic water-containing medium
- the method of dispersing as it is include, for example, the method described as the solid phase decomposition step.
- the resulting low molecular weight product hyaluronic acid having an average molecular weight of 3,500 or less and / or a salt thereof) dissolves in the acidic water constituting the acidic water-containing medium.
- browning occurs due to the acid contained in the acidic water, or the low molecular weight product is decomposed by the acid to produce a by-product such as a monosaccharide.
- a by-product such as a monosaccharide.
- hyaluronic acid and / or a salt thereof having high whiteness and low content of by-products can be obtained.
- the hyaluronic acid and / or salt thereof obtained through the spray-drying step is the hyaluronic acid and / or salt thereof obtained through the freeze-drying step (usually a fluffy cotton-like solid is obtained)
- the particle size variation is smaller and the content of a trace amount of impurities is smaller.
- the method for producing hyaluronic acid and / or a salt thereof comprises spray drying or drying a liquid containing 8% by mass to 35% by mass of hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or less. And lyophilizing to obtain a method for producing solid hyaluronic acid and / or a salt thereof.
- the average molecular weight of hyaluronic acid and / or a salt thereof to be spray-dried is preferably 3,500 or less, more preferably 2,800 or less, on the other hand, 1,000 or more. It is preferable that it is 1,200 or more.
- hyaluronic acid and / or a salt thereof having an average molecular weight of 3,500 or less has a lower viscosity than that of polymeric hyaluronic acid and / or a salt thereof, and thus is a target for spray drying in the production method according to the present embodiment.
- concentration in the liquid from 8% by mass to 35% by mass
- particulate hyaluronic acid and / or a salt thereof having a high bulk density and a small variation in particle diameter can be obtained.
- a food product according to an embodiment of the present invention includes hyaluronic acid and / or a salt thereof according to the above embodiment. More specifically, the food according to the present embodiment can contain 0.1% by mass or more and 100% by mass or less of the hyaluronic acid and / or salt thereof according to the above embodiment.
- the embodiment of the food containing the hyaluronic acid and / or salt thereof is not particularly limited.
- processed foods such as cooked rice as a staple food, bread making, canned retort canned foods, frozen foods, prepared dishes, dried foods, mayonnaise
- general foods such as regular seasonings, beverages, confectionery, desserts, supplements such as liquid, gel or soft capsules, foods for specific health use that are permitted to express physiological functions can be listed. .
- the aspect of the food according to the present embodiment is not particularly limited, for example, gum, candy, gummy candy, troche-like food, jelly beverage, cooked rice food, bread making, canned retort, frozen food, side dish, dried food, mayonnaise
- General foods such as regular seasonings, beverages, confectionery, desserts, supplements, etc., and general health foods that are permitted to express physiological functions are listed. Of these, in terms of convenience, Supplements are preferred.
- the supplements may be in the form of solids such as tablets, powders, fine particles, granules, capsules (hard capsules, soft capsules), fluids, suspensions, jellies, syrups, etc. Is mentioned.
- Hyaluronic acid and / or a salt thereof is a biological substance, so even if it is ingested in large quantities, it is considered that there is no side effect or very low, but the amount of hyaluronic acid and / or a salt thereof according to the present embodiment to be ingested as a food 1 mg to 1000 mg, preferably 15 mg to 300 mg per day.
- the cosmetic according to one embodiment of the present invention includes hyaluronic acid and / or a salt thereof according to the above embodiment.
- the use mode of the cosmetic according to the present embodiment is not particularly limited, but is preferably applied to or ingested on the surface of a living tissue, and in particular applied to or contacted with skin such as the face, arms, fingers, feet, and joints. It is preferable to do so.
- Examples of cosmetics according to this embodiment include skin cosmetics.
- skin cosmetics By using the hyaluronic acid and / or salt thereof according to the above embodiment for skin cosmetics, it has an appropriate viscosity and has a high water retention effect, so moisturizes the skin and gives the skin a feeling of bulkiness. Can be improved.
- Examples of the cosmetic for skin according to the present embodiment include, for example, face wash, cleanser, lotion (for example, whitening lotion), cream (for example, vanishing cream, cold cream), milky lotion, cosmetic liquid, pack ( For example, jelly-type peel-off type, paste-type wipe-off type, powder-type wash-out type), cleansing, foundation, lipstick, lip balm, lip gloss, lip liner, blusher, shaving lotion, after sun lotion, deodorant lotion, body lotion (hand care lotion) Body oils, soaps, and bath additives.
- the following ingredients may be further blended in the cosmetic according to the present embodiment.
- the component include cationized polysaccharides (eg, cationized hyaluronic acid, cationized hydroxyethyl cellulose, cationized guar gum, cationized starch, cationized locust bean gum, cationized dextran, cationized chitosan, and cationized honey).
- cationized polysaccharides eg, cationized hyaluronic acid, cationized hydroxyethyl cellulose, cationized guar gum, cationized starch, cationized locust bean gum, cationized dextran, cationized chitosan, and cationized honey).
- Anionic surfactants eg, alkylbenzene sulfonates, polyoxyalkylene alkyl ether sulfates, alkyl sulfates, olefin sulfonates, fatty acid salts, dialkylsulfosuccinates, etc.
- nonionic surfactants eg , Polyoxyethylene fatty acid esters, polyoxyethylene hydrogenated castor oil derivatives, etc.
- cationic surfactants eg, alkyltrimethylammonium salts, dialkyldimethylammonium salts, alkylpyridines
- Um salt stearyltrimethylammonium chloride, etc.
- amphoteric surfactant eg, alkylbetaine, alkylamidopropylbetaine, imidazolinium betaine, egg yolk lecithin, soybean lecithin, etc.
- oil eg, silicone, silicone derivatives, liquid paraffin, Squalane, beeswax
- a pharmaceutical product according to an embodiment of the present invention includes hyaluronic acid and / or a salt thereof according to the above embodiment. More specifically, the pharmaceutical product according to the present embodiment can contain 5% by mass or more and 100% by mass or less of hyaluronic acid and / or a salt thereof according to the above embodiment.
- the pharmaceutical product according to this embodiment can contain other raw materials in addition to the hyaluronic acid and / or salt thereof according to the above-described embodiment as long as the effects of the present invention are not impaired.
- raw materials are water, excipients, antioxidants, preservatives, wetting agents, thickeners, buffers, adsorbents, solvents, emulsifiers, stabilizers, surfactants, lubricants, Water-soluble polymers, sweeteners, flavoring agents, acidulants, alcohols and the like can be mentioned.
- the dosage form of the pharmaceutical product according to this embodiment is not particularly limited, but when the pharmaceutical product is taken orally, for example, a solid preparation such as a tablet, powder, fine granule, granule, capsule, pill, etc., liquid, suspension Orally administrable agents such as liquids such as sachets, syrups and emulsions.
- the amount of hyaluronic acid and / or a salt thereof taken as a pharmaceutical product according to the present embodiment can be 10 mg to 1,000 mg, preferably 100 mg to 500 mg per day.
- the number of administrations can be selected once or multiple times per day depending on the symptoms.
- the pharmaceutical agent according to the present embodiment may be blended with a bulking agent, a binder, a lubricant, a preservative, an antioxidant, a fragrance, a sweetener, a sour agent, an excipient, and the like. It can.
- vitamins such as vitamin C, vitamin B2, vitamin B12, and vitamin E, various nutritional components such as nutritional components such as nucleic acid, chondroitin sulfate, and collagen, and mineral components such as iron and zinc can also be blended.
- the hyaluronic acid and / or salt thereof has an average molecular weight of 3,500 or less, and one or more of the following features (1) to (13) (two, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13).
- the bulk density is greater than 0.25 g / cm 3 .
- the purity is 90% or more.
- the b value representing the hue of the color is 10 or less.
- the average particle size is 10 ⁇ m or more and 35 ⁇ m or less.
- the standard deviation of the particle diameter is 0.1 or more and 0.3 or less.
- the chlorine content is 1% by mass or less.
- the sulfur content is 1% by mass or less.
- the ratio of disaccharide is 1% by mass or more and 30% by mass or less. (9) Does not contain hyaluronic acid degrading enzyme. (10) The ratio of octasaccharide is 1% by mass or more and 30% by mass or less.
- the total of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide is 5% by mass or more and 80% by mass or less.
- the kinematic viscosity of the 5% by mass aqueous solution is 2.0 mm 2 / s or less.
- the proportion of monosaccharide is 3% by mass or less.
- the hyaluronic acid and / or salt thereof according to the present embodiment has the same effects as the hyaluronic acid and / or salt thereof according to the embodiment.
- Example 1 Preparation of hyaluronic acid> About 5 kg of raw material hyaluronic acid with a molecular weight of 10,000 is wetted with 1 kg of ethanol and added to 25 L of 2% hydrochloric acid (pH 1.0, 25 kg) in a 50 L tank equipped with a stirrer and jacket, and contains about 16% by mass of raw material hyaluronic acid. An acidic raw material hyaluronic acid aqueous solution (pH about 1) was prepared, and this was kept at 70 ° C. for 5 hours to carry out hydrolysis (liquid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded and diluted with 8 L of water, and the resin was removed with an 80 mesh filter. 2 kg of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: 12% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of raw material hyaluronic acid as the content of hyaluronic acid) was spray-dried (heater temperature: 180 ) To obtain 4.5 kg of hyaluronic acid as a white fine powder (yield: about 90%).
- the obtained hyaluronic acid had a molecular weight calculated from HPLC measurement of 2,200, a b value of 2.2, and an L value of 95.
- Table 1 shows the results of measuring the bulk density, particle size, particle size distribution, and chlorine content of this hyaluronic acid.
- HPLC measurement was performed on the hyaluronic acid of Example 1, Examples 2 to 8, which will be described later, and hyaluronic acid of Comparative Examples 2 to 4, 7 and 8.
- the HPLC measurement conditions are as follows. From the measurement results of HPLC, according to the method described in the above embodiment, the average molecular weight and disaccharide and tetrasaccharide of hyaluronic acid of Examples 1 to 8 and hyaluronic acid of Comparative Examples 2 to 4, 7 and 8 described later are used. The ratios of hexasaccharide and octasaccharide were calculated.
- HPLC analyzer trade name “Alliance PDA system”, manufactured by Nihon Waters Co., Ltd.
- Analytical sample 0.1% of hyaluronic acid (w / v ) Aqueous solution
- Injection volume of 0.1% (w / v) aqueous solution of hyaluronic acid 20 ⁇ L
- Mobile phase 0.003 M phosphate buffer (containing 0.15 M NaCl, pH 7.0)
- a value obtained by multiplying the molecular weight of each peak (for example, molecular weight 400 for disaccharides) by the peak area is calculated, and the values calculated for each peak are integrated. Furthermore, the average molecular weight can be calculated by dividing it by the total peak area.
- ⁇ Comparative Example 1 Preparation of hyaluronic acid> About 2 kg of dried hyaluronic acid having a molecular weight of 10,000 is added to 25 L of 2% hydrochloric acid (pH 1.0, 25 kg) in a 50 L tank equipped with a stirrer and a jacket, and acidic raw material hyaluronic acid containing about 7% by mass of raw material hyaluronic acid is added. An aqueous solution (pH about 1) was prepared, and this was kept at 70 ° C. for 5 hours to carry out hydrolysis (liquid phase decomposition step).
- the obtained solution (concentration of hyaluronic acid: 4% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of raw material hyaluronic acid as the content of hyaluronic acid) was spray-dried (heater temperature: 180 When it was dried by (° C.), it became mist and hyaluronic acid could not be recovered.
- Comparative Example 2 Preparation of hyaluronic acid> 1.9 kg of white fine powder hyaluronic acid of Comparative Example 2 was obtained in the same manner as Comparative Example 1 except that freeze-drying was performed instead of spray drying.
- Example 2 Preparation of hyaluronic acid> A 200 L tank equipped with a stirrer and a jacket was filled with 28 L (28 kg) of 8% hydrochloric acid and 100 L of ethanol, and heated to 70 ° C. while stirring. After reaching 70 ° C., 5 kg of the starting material hyaluronic acid having an average molecular weight of 300,000 was charged into the tank while stirring. While heating to maintain the temperature of hydrochloric acid-containing aqueous ethanol (pH 0.2) at 70 ° C., stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 12 L of water and diluted, and the resin was removed with an 80 mesh filter. 2 kg of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: 11% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of the starting material hyaluronic acid as the content of hyaluronic acid) was spray dried (heater temperature: 180 ° C.) to obtain 4.5 kg of hyaluronic acid as white fine powder (yield: about 90%).
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 3 Preparation of hyaluronic acid>
- the volume of the tank used, the mass of the starting material hyaluronic acid, the mass of hydrochloric acid, the mass of ethanol, and the mass of sodium hydroxide were all changed to 1/100, scaled down, and spray dried.
- the hyaluronic acid of Example 3 was obtained in the same manner except that the concentration of the hyaluronic acid solution was 14% by mass.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: 14% by mass, where the concentration of hyaluronic acid was calculated by regarding the addition amount of the starting material hyaluronic acid as the content of hyaluronic acid) was spray-dried (heater temperature: 180 g) to obtain 46 g (yield: about 92%) of hyaluronic acid as white fine powder.
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 4 Preparation of hyaluronic acid>
- a solution containing 11% by mass of hyaluronic acid of Example 4 was prepared in the same manner except that water was added to the solution obtained after removing the resin to adjust the concentration of hyaluronic acid. Obtained. This solution was freeze-dried to obtain hyaluronic acid of Example 4.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less. A part of the obtained solution diluted 1.25 times (concentration of hyaluronic acid: 11% by mass, where the concentration of hyaluronic acid is regarded as the amount of hyaluronic acid added as the starting material hyaluronic acid content) was calculated by freeze-drying to obtain white fine powder of hyaluronic acid. In addition, when the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- Example 3 Preparation of hyaluronic acid>
- water was added to the solution obtained after removing the resin to adjust the concentration of hyaluronic acid. 6 mass%) was obtained.
- This solution was freeze-dried to obtain hyaluronic acid of Comparative Example 3.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less. A part of the resulting solution diluted 22 times (concentration of hyaluronic acid: 0.6% by mass, where the concentration of hyaluronic acid is regarded as the amount of hyaluronic acid added as the starting material hyaluronic acid content) was calculated by freeze-drying to obtain white fine powder of hyaluronic acid. In addition, when the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- Comparative Example 4 Preparation of hyaluronic acid>
- the solution containing 6% by mass of hyaluronic acid of Comparative Example 4 was prepared in the same manner as Comparative Example 3 except that the amount of water added to the solution obtained after removing the resin was changed. Obtained. This solution was freeze-dried to obtain hyaluronic acid of Comparative Example 4.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less. A part of the obtained solution diluted 2.5 times (concentration of hyaluronic acid: 6% by mass, where the concentration of hyaluronic acid is regarded as the amount of hyaluronic acid added as the starting material hyaluronic acid content) was calculated by freeze-drying to obtain white fine powder of hyaluronic acid. In addition, when the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- Example 5 Preparation of hyaluronic acid>
- a solution containing 6% by mass of hyaluronic acid of Comparative Example 5 was prepared in the same manner as in Comparative Example 3, except that the amount of water added to the solution obtained after removing the resin was changed. Obtained. When this solution was spray-dried in the same manner as in Example 2, it became mist-like and hyaluronic acid could not be recovered.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less. A part of the obtained solution diluted 2.5 times (concentration of hyaluronic acid: 6% by mass, where the concentration of hyaluronic acid is regarded as the amount of hyaluronic acid added as the starting material hyaluronic acid content) Calculated) was spray-dried to form a mist, and hyaluronic acid could not be recovered.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 120 mL of water and diluted, and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- the obtained solution (concentration of hyaluronic acid: 15% by mass, where the concentration of hyaluronic acid was calculated by regarding the addition amount of the starting material hyaluronic acid as the content of hyaluronic acid) was dried by spray drying. However, browned hyaluronic acid was obtained, and the obtained hyaluronic acid had a b value of 10 or more. The proportion of monosaccharide was 4%.
- Example 7 Preparation of hyaluronic acid>
- the hydrolysis time of the solid phase decomposition step was mainly set to 2 hours, and before treatment with an anion exchange resin, sodium hydroxide was added and neutralized, and then ethanol was added and hyaluronic acid was added.
- the hyaluronic acid of Comparative Example 7 was obtained.
- a 500 L tank equipped with a stirrer and a jacket was filled with 28 L (28 kg) of 8% hydrochloric acid and 100 L of ethanol, and heated with stirring to a liquid temperature of 70 ° C. After reaching 70 ° C., 5 kg of the starting material hyaluronic acid having an average molecular weight of 300,000 was charged into the tank while stirring. While heating to maintain the temperature of hydrochloric acid-containing aqueous ethanol (pH 0.2) at 70 ° C., stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the obtained solution (concentration of hyaluronic acid: 15% by mass, where the concentration of hyaluronic acid was calculated by regarding the addition amount of the starting material hyaluronic acid as the content of hyaluronic acid) was dried by spray drying, As a result, 4.5 kg of hyaluronic acid (yield: about 90%) was obtained as white fine powder.
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 5 Preparation of hyaluronic acid> A 200 L tank equipped with a stirrer and a jacket was filled with 14 L (14 kg) of 8% hydrochloric acid and 53 L of ethanol, and heated to 70 ° C. while stirring. After reaching 70 ° C., 5 kg of the starting material hyaluronic acid having an average molecular weight of 300,000 was charged into the tank while stirring. While heating to maintain the temperature of hydrochloric acid-containing aqueous ethanol (pH 0.2) at 70 ° C., stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded and diluted with 8 L of water, and the resin was removed with an 80 mesh filter. 2 kg of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: 12% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of the starting material hyaluronic acid as the content of hyaluronic acid) was dried by lyophilization, As a result, 4.5 kg of hyaluronic acid (yield: about 90%) was obtained as white fine powder.
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 6 Preparation of hyaluronic acid> A 200 L tank equipped with a stirrer and a jacket was filled with 14 L (14 kg) of 8% hydrochloric acid and 53 L of ethanol, and heated to 70 ° C. while stirring. After reaching 70 ° C., 5 kg of the starting material hyaluronic acid having an average molecular weight of 300,000 was charged into the tank while stirring. While heating to maintain the temperature of hydrochloric acid-containing aqueous ethanol (pH 0.2) at 70 ° C., stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded and diluted with 8 L of water, and the resin was removed with an 80 mesh filter. 2 kg of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: 12% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of the starting material hyaluronic acid as the content of hyaluronic acid) was dried by lyophilization, As a result, 4.5 kg of hyaluronic acid (yield: about 90%) was obtained as white fine powder.
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 7 Preparation of hyaluronic acid>
- a solution containing 22% by mass of hyaluronic acid of Example 7 was obtained in the same manner except that the solution obtained after removing the resin was used as it was without being diluted with water. This solution was spray-dried to obtain hyaluronic acid of Example 7.
- a 2 L beaker was filled with 280 mL (280 g) of 8% hydrochloric acid and 1 L of ethanol, and heated in a hot water bath so that the liquid temperature became 70 ° C. while stirring.
- 50 g of the starting material hyaluronic acid having an average molecular weight of 300,000 was put into a beaker while stirring.
- stirring was performed so that the hyaluronic acid fine powder was in a dispersed state, and stirring was performed for 1 hour (solid phase decomposition step).
- the liquid containing the obtained hydrolyzate was subjected to anion exchange resin treatment (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), and the resin was removed with an 80 mesh filter. 20 g of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- the obtained solution concentration of hyaluronic acid: 22% by mass, where the concentration of hyaluronic acid was calculated by regarding the addition amount of the starting material hyaluronic acid as the content of hyaluronic acid
- 45 g (yield: 90%) of hyaluronic acid as white fine powder was obtained.
- the average molecular weight of the raw material hyaluronic acid obtained in the solid phase decomposition step was separately measured, it was about 10,000.
- Example 8 Preparation of hyaluronic acid>
- a solution containing 22% by mass of hyaluronic acid of Example 8 was obtained by the same method except that ethanol used in the solid phase decomposition step was replaced with methanol. This solution was spray-dried to obtain hyaluronic acid of Example 8.
- the hyaluronic acid of Example 8 has molecular weight, purity of hyaluronic acid, b value, bulk density, particle size distribution (including average particle size and standard deviation of particle size), chlorine content, proportion of two sugars, disaccharides, The total ratio of sugar, hexasaccharide and octasaccharide was the same as in Example 7.
- ⁇ Comparative Example 9 Preparation of hyaluronic acid> About 5 kg of raw material hyaluronic acid with a molecular weight of 110,000 is wetted with 1 kg of ethanol and added to 25 L of 2% hydrochloric acid (pH 1.0, 25 kg) in a 50 L tank equipped with a stirrer and jacket, and contains about 16% by mass of raw material hyaluronic acid. When an attempt was made to prepare an acidic raw material hyaluronic acid aqueous solution (pH about 1), the hyaluronic acid solution became very viscous and could not be stirred.
- ⁇ Comparative Example 10 Preparation of hyaluronic acid> About 0.2 kg of raw material hyaluronic acid having a molecular weight of 110,000 is wetted with 0.05 kg of ethanol, and added to 25 L of 2% hydrochloric acid (pH 1.0, 25 kg) in a 50 L tank equipped with a stirrer and a jacket. An acidic raw material hyaluronic acid aqueous solution (pH about 1) containing 0.8% by mass was prepared, and this was held at 70 ° C. for 10 hours to carry out hydrolysis (liquid phase decomposition step).
- the liquid containing the obtained hydrolyzate was treated with an anion exchange resin (trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical), extruded with 8 L of water and diluted, and the resin was removed with an 80 mesh filter. 2 kg of 25% aqueous sodium hydroxide solution was added to adjust the pH to 4.0 or more and 6.5 or less.
- an anion exchange resin trade name: Diaion or Sepabeads, manufactured by Mitsubishi Chemical
- the obtained solution (concentration of hyaluronic acid: about 0.6% by mass, where the concentration of hyaluronic acid was calculated by regarding the added amount of raw material hyaluronic acid as the content of hyaluronic acid) was spray-dried (heater When it was dried at a temperature of 180 ° C., it became a mist and hyaluronic acid could not be recovered.
- the hyaluronic acids of Examples 1 to 7 have a bulk density greater than 0.25 g / cm 3 , little variation in particle diameter, and both chlorine content and sulfur content are 1% by mass or less.
- the ratio of disaccharide is 1% by mass or more and 30% by mass or less.
- the ratio of octasaccharide is 1% by mass to 30% by mass, and the total of disaccharide, tetrasaccharide, hexasaccharide and octasaccharide is 5% by mass to 80% by mass. % Can be understood.
- Examples 1 to 7 and Comparative Examples 2 to 4, 7, and 8 were tableted to prepare tablets, and the tableting suitability was compared.
- the hyaluronic acid of Examples 1 to 7 was Compared with the hyaluronic acids of Comparative Examples 2 to 4, 7, and 8, the binding force was high and tableting suitability was high.
- the tablet containing the hyaluronic acid of Examples 3 to 7 having a low chlorine content was highly tabletable.
- the tablets containing hyaluronic acid of Examples 1, 3 and 7 having the smallest average particle diameter and the small standard deviation of the particle diameters were particularly excellent in handleability because the powder was difficult to fly.
- ⁇ Combination Example 1 Essence>
- a cosmetic liquid (whitening moisturizing essence) in which the hyaluronic acid obtained in Example 1 was blended was prepared according to the formulation described below.
- the hyaluronic acid obtained in Example 1 used in this Formulation Example has an appropriate binding property, and it is difficult for powder to fly, and formulation in this Formulation Example was easy.
- Hyaluronic acid (Example 1) 1.0% Hydrolyzed hyaluronic acid 0.1% 1,3-butylene glycol 5.0% Glycerin 1.5% POE sorbitan monostearate 1.0% Sorbitan monostearate 0.5% Xanthan gum 0.2% Sodium alginate 0.2% Carboxyvinyl polymer 0.2% Potassium hydroxide 0.1% Olive oil 0.2% Tocopherol 0.1% EDTA-2 sodium 0.02% Arginine 0.15% Dipotassium glycyrrhizinate 0.05% Arbutin 0.2% Retinol palmitate 0.2% Cousin extract 0.2% Seaweed extract 0.2% Tranexamic acid 0.1% Elastin 0.1% Collagen 0.1% Magnesium phosphate ascorbate 0.1% Sodium citrate 1.0% Citric acid 0.1% Propylparaben 0.1% Methylparaben 0.15% Perfume appropriate amount Purified water remaining
- ⁇ Formulation example 2 soft capsule>
- soft capsules blended with the hyaluronic acid obtained in Example 1 were prepared according to the formulation described below.
- the hyaluronic acid obtained in Example 1 used in this Formulation Example has an appropriate binding property and has a high filling rate into the capsule, and in this Formulation Example, formulation was easy.
- Hyaluronic acid (Example 1) 20% Olive oil 35% Beeswax 5% Medium chain triglyceride 5% Gelatin 25% Glycerin 10%
- ⁇ Formulation Example 3 Powder>
- a powder (granule) blended with the hyaluronic acid obtained in Example 1 was prepared according to the formulation described below.
- the hyaluronic acid obtained in Example 1 used in this Formulation Example has an appropriate binding property, and it is difficult for powder to fly, and formulation in this Formulation Example was easy.
- Hyaluronic acid (Example 1) 10% Lactose 60% Corn starch 25% Hypromellose 5%
- ⁇ Formulation Example 4 Tablet>
- a tablet containing the hyaluronic acid obtained in Example 1 was prepared according to the formulation described below. Since the hyaluronic acid obtained in Example 1 used in this Formulation Example has an appropriate binding property and excellent tableting suitability, it was easy to formulate in this Formulation Example.
- Hyaluronic acid (Example 1) 25% Lactose 24% 20% crystalline cellulose Corn starch 15% Dextrin 15% Silicon dioxide 1%
- ⁇ Formulation example 5 jelly beverage>
- a white peach jelly beverage containing a spout pouch blended with the hyaluronic acid obtained in Example 1 was prepared according to the formulation described below.
- the hyaluronic acid obtained in Example 1 used in this blending example had an appropriate binding property, and it was difficult for powder to fly, and preparation was easy in this blending example.
- Hyaluronic acid (Example 1) 0.20% Xanthan gum 1.00% Carrageenan 0.5% Dextrin alcohol 3.0% Sucralose 1% 4-fold concentrated white peach juice 5.00% Citric acid 0.60% Sodium citrate 0.20% L-ascorbic acid 0.10% Peach flavoring 0.20% Purified water remaining
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
前記調製する工程で得られた前記酸性原料ヒアルロン酸溶液中で前記原料ヒアルロン酸および/またはその塩を酸加水分解する工程と、
前記酸加水分解により得られた加水分解物を含む酸性溶液を陰イオン交換樹脂で処理する工程と、
前記樹脂処理された前記加水分解物を噴霧乾燥または凍結乾燥させる工程と、を含み、
前記酸性原料ヒアルロン酸溶液は、15質量%以上35質量%以下の前記原料ヒアルロン酸および/またはその塩を含み、かつ、
前記酸性原料ヒアルロン酸溶液は、前記原料ヒアルロン酸および/またはその塩100質量部に対して、5質量部以上60質量部以下の前記低級アルコールを含む。
本発明の一実施形態に係るヒアルロン酸および/またはその塩は、平均分子量が3,500以下であり、2糖の割合が1質量%以上30質量%以下であり、塩素含量および硫黄含量がいずれも1質量%以下であり、かつ、かさ密度(bulk density)が0.25g/cm3よりも大きい。
本発明において、「ヒアルロン酸」とは、グルクロン酸とN-アセチルグルコサミンとの2糖からなる繰り返し構成単位を1以上有する多糖類をいう。また、「ヒアルロン酸の塩」としては、特に限定されないが、食品または薬学上許容しうる塩であることが好ましく、例えば、ナトリウム塩、カリウム塩、カルシウム塩、亜鉛塩、マグネシウム塩、アンモニウム塩等が挙げられる。
本発明において、「かさ密度」は、「第十六改正日本薬局方、3.粉体物性測定法、3.01 かさ密度およびタップ密度測定法」に記載の方法に準じて測定された値である。本実施形態に係るヒアルロン酸および/またはその塩は、平均分子量が3,500以下であり、かつ、かさ密度が0.25g/cm3よりも大きいことにより、低分子でありながら、打錠適性(tableting adequacy)等の取扱性(handling ability)に優れている。
本実施形態に係るヒアルロン酸および/またはその塩は、純度をより高くできる点で、平均分子量が3,500以下であり、2,500以下であることが好ましく、一方、通常800以上であり、1,000以上であることが好ましい。なお、本発明において、ヒアルロン酸および/またはその塩の平均分子量は、後述するHPLCを用いた方法にて測定することができる。
本実施形態に係るヒアルロン酸および/またはその塩は、純度が90%以上であることができ、95%以上であることが好ましく、98%以上であることがより好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、色の色相を表すb値(以下、単に「b値」ともいう)が10以下であることができ、8以下であることが好ましく、5以下であることがより好ましく、通常0以上である。
本実施形態に係るヒアルロン酸および/またはその塩によれば、塩素含量および硫黄含量がいずれも1質量%以下であることにより、打錠適性に優れている。ヒアルロン酸および/またはその塩中の塩素含量または硫黄含量が1質量%を超えると、塩化ナトリウム等の塩素の金属塩や硫酸ナトリウムなどの硫化物の金属塩が増えることによって、粒子形状の不均一性が増し、打錠時の結着力を弱めると推察される。これに対して、本実施形態に係るヒアルロン酸および/またはその塩は、塩素含量および硫黄含量がいずれも1質量%以下であり、塩素の含量および硫黄の含量が少ないことから、粒子形状の均一性が増し、打錠時の結着力が高められるため、打錠適性が向上する。
本実施形態に係るヒアルロン酸および/またはその塩は、打錠適性により優れている点で、平均粒子径が10μm以上35μm以下であることができ、15μm以上であることが好ましく、一方、30μm以下であることが好ましい。
粒子径の標準偏差(standard deviation)は、本実施形態に係るヒアルロン酸および/またはその塩の粒子径のばらつきを示す指標である。本実施形態に係るヒアルロン酸および/またはその塩は、粒子径のばらつきが少ないため、密度をより高めることができることにより、打錠適性をより高めることができる点で、粒子径の標準偏差が0.1以上0.3以下であることができ、0.15以上であることが好ましく、一方、0.25以下であることが好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、ヒアルロン酸本来の生理機能を発揮できる点で、2糖の割合が1質量%以上30質量%以下であり、5質量%以上であることが好ましく、8質量%以上であることがより好ましく、一方、25質量%以下であることが好ましく、20質量%以下であることがより好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、抗原性をより低減できる点で、ヒアルロン酸分解酵素を含有しないことができる。本発明において、「ヒアルロン酸分解酵素を含有しない」とは、本実施形態に係るヒアルロン酸および/またはその塩におけるヒアルロン酸分解酵素の含有量が1質量%以下であることをいう。抗原性が低減されている点で、例えば、本実施形態に係るヒアルロン酸および/またはその塩は、酸分解(例えば後述する本実施形態に係る製造方法)により得られた、酸分解ヒアルロン酸および/またはその塩であることが好ましく、より具体的には、製造方法のいずれかで酸分解を経て得られた酸分解ヒアルロン酸および/またはその塩であることがより好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、8糖に由来する生理活性をより確実に発揮できる点で、8糖の割合が1質量%以上30質量%以下であることができ、5質量%以上であることがより好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、2糖、4糖、6糖および8糖の合計が5質量%以上80質量%以下であることができ、10質量%以上であることが好ましく、一方、70質量%以下であることが好ましい。
本実施形態に係るヒアルロン酸および/またはその塩は、該ヒアルロン酸および/またはその塩の5質量%水溶液の動粘度が2.0mm2/s以下(好ましくは、1.5mm2/s以下、より好ましくは1.3mm2/s以下)であることができる。
本実施形態に係るヒアルロン酸および/またはその塩によれば、平均分子量が3,500以下であり、2糖の割合が1質量%以上30質量%以下であり、塩素含量および硫黄含量がいずれも1質量%以下であり、かつ、かさ密度が0.25g/cm3よりも大きいことにより、例えば打錠適性等の取扱性に優れている。
本発明の一実施形態に係るヒアルロン酸および/またはその塩の製造方法(以下、「第1製造方法」ともいう。)は、低級アルコール(lower alcohol)と、平均分子量が3,500以上10万以下の原料ヒアルロン酸および/またはその塩と、酸と、を含む酸性原料ヒアルロン酸溶液を調製する工程と、前記調製する工程で得られた前記酸性原料ヒアルロン酸溶液中で前記原料ヒアルロン酸および/またはその塩を酸加水分解する工程(以下、「液相(liquid phase)分解工程」ともいう。)と、前記酸加水分解により得られた加水分解物を含む酸性溶液を陰イオン交換樹脂で処理する工程(以下、「陰イオン交換樹脂処理工程」ともいう。)と、前記樹脂処理された前記加水分解物を噴霧乾燥(spray-drying)または凍結乾燥(freeze-drying)させる工程(以下、「噴霧乾燥工程」または「凍結乾燥工程」ともいう。)と、を含み、前記酸性原料ヒアルロン酸溶液は、15質量%以上35質量%以下の前記原料ヒアルロン酸および/またはその塩を含み、かつ、前記酸性原料ヒアルロン酸溶液は、前記原料ヒアルロン酸および/またはその塩100質量部に対して、5質量部以上60質量部以下の前記低級アルコールを含む。
酸性原料ヒアルロン酸溶液を調製する工程では、低級アルコールと、平均分子量が3,500以上10万以下の原料ヒアルロン酸および/またはその塩と、酸と、を含む酸性原料ヒアルロン酸溶液を調製する。
本実施形態に係る製造方法において、分子量が3,500以下であり白色度が高いヒアルロン酸および/またはその塩を得ることができる点で、酸性原料ヒアルロン酸溶液に含まれる原料ヒアルロン酸および/またはその塩の分子量は5,000以上であることが好ましく、6,000以上であることがより好ましく、8,000以上であることが好ましく、一方、5万以下であることが好ましく、2万以下であることがより好ましい。
本発明において、原料ヒアルロン酸および/またはその塩(ならびに、後述する出発原料ヒアルロン酸および/またはその塩)の平均分子量は、下記の方法にて測定することができる。即ち、約0.05gのヒアルロン酸(本品)を精密に量り、0.2mol/L濃度の塩化ナトリウム溶液に溶かし、正確に100mLとした溶液及びこの溶液8mL、12mL並びに16mLを正確に量り、それぞれに0.2mol/L濃度の塩化ナトリウム溶液を加えて正確に20mLとした溶液を試料溶液とする。この試料溶液および0.2mol/L濃度の塩化ナトリウム溶液につき、日本薬局方(第十六改正)一般試験法の粘度測定法(第1法毛細管粘度測定法)により30.0±0.1℃で比粘度を測定し(式(A))、各濃度における還元粘度を算出する(式(B))。還元粘度を縦軸に、本品の換算した乾燥物に対する濃度(g/100mL)を横軸にとってグラフを描き、各点を結ぶ直線と縦軸との交点から極限粘度を求める。ここで求められた極限粘度をLaurentの式(式(C))に代入し、平均分子量を算出する(Torvard C Laurent,Marion Ryan,and Adolph Pietruszkiewicz,”Fractionation of hyaluronic Acid”,Biochemina et Biophysica Acta.,42,476-485(1960)、四方田千佳子、「ヒアルロン酸ナトリウム製剤のSEC-MALLSによる分子量評価」、国立衛研報、第121号,030-033(2003))。
(式A)
比粘度={試料溶液の所要流下秒数)/(0.2mol/L塩化ナトリウム溶液の所要流下秒数)}-1
(式B)
還元粘度(dL/g)=比粘度/(本品の換算した乾燥物に対する濃度g/100mL))
(式C)
極限粘度(dL/g)=3.6×10-4M0.78
M:平均分子量
酸性原料ヒアルロン酸溶液では、原料ヒアルロン酸および/またはその塩が酸性原料ヒアルロン酸溶液中に溶解する濃度にするのが好ましい。
原料ヒアルロン酸および/またはその塩の溶解性に優れている点で、酸性原料ヒアルロン酸溶液に使用される溶媒は含水溶媒(好ましくは水)であることが好ましいが、原料ヒアルロン酸および/またはその塩を溶解させることができるのであれば、該溶媒は、水、または、水と混和する有機溶媒を30質量%以下含む含水溶媒であってもよい。
本発明において「低級アルコール」とは、炭素原子数1、2または3のアルコールをいい、例えば、メタノール、エタノール、1-プロパノール、および2-プロパノールが挙げられる。このうち、1種または2種以上を低級アルコールとして使用することができる。低級アルコールとしては、例えば、メタノールおよび/またはエタノールが好ましく、エタノールがより好ましい。
前記酸性原料ヒアルロン酸溶液に含まれる酸は、該酸性原料ヒアルロン酸溶液のpHを酸性に調整できる酸であれば、いずれの酸を使用することができる。酸の使用量を低減できる観点から、該酸は例えば、塩酸、硫酸、臭化水素酸、硝酸、リン酸等の無機酸、酢酸、クエン酸、スルホン基含有有機酸(例えば、パラトルエンスルホン酸、トリフルオロメタンスルホン酸)、フッ素原子含有有機酸(例えば、トリフルオロ酢酸)等の有機酸を使用することができる。
前記酸性原料ヒアルロン酸溶液を調製する工程では、前記低級アルコールと、前記原料ヒアルロン酸および/またはその塩との混合物(ここで、前記混合物は、前記原料ヒアルロン酸および/またはその塩100質量部に対して5質量部以上60質量部以下の前記低級アルコールを含む。)を、酸を含む液(酸性液)に添加することにより、前記酸性原料ヒアルロン酸溶液を調製することができる。
また、液相分解工程において、原料ヒアルロン酸および/またはその塩の褐変を防止し、かつ原料ヒアルロン酸および/またはその塩の低分子化を達成できる点で、前記酸性原料ヒアルロン酸溶液のpHは0.2以上2以下であることができ、0.3以上であることが好ましく、0.5以上であることがより好ましく、0.8以上であることがさらに好ましく、一方、1.8以下であることが好ましく、1.5以下であることがより好ましく、1.0以下であることがさらに好ましい。
液相分解工程(第1低分子化工程)では、平均分子量が3,500以上10万以下の原料ヒアルロン酸および/またはその塩を15質量%以上35質量%以下含む酸性原料ヒアルロン酸溶液中に保持して、前記原料ヒアルロン酸および/またはその塩を酸加水分解する。これにより、原料ヒアルロン酸および/またはその塩が酸加水分解により低分子化されて、分子量がより小さい加水分解物(ヒアルロン酸および/またはその塩)が得られる。
液相分解工程では、低分子化されたヒアルロン酸および/またはその塩の褐変を防ぐことができる点から、反応液の温度は通常85℃以下(好ましくは80℃以下)であることが好ましく、60℃以上(好ましくは65℃以上)であることがより好ましい。
液相分解工程では、低分子化されたヒアルロン酸および/またはその塩の褐変を防ぐことができる点から、反応時間は通常30分以上10時間以下であることが好ましく、60分以上8時間以下であることがより好ましい。
液相分解工程によって、平均分子量が3,500以下(好ましくは2,800以下、より好ましくは2,500以下、一方、好ましくは1,000以上、より好ましくは1,200以上)のヒアルロン酸および/またはその塩を得ることができる。
本実施形態に係る製造方法では、前記液相分解工程の後、前記酸加水分解により得られた加水分解物を含む酸性溶液を陰イオン交換樹脂で処理する。ここで、加水分解物は、原料ヒアルロン酸および/またはその塩が低分子化されて得られた、原料ヒアルロン酸および/またはその塩よりも分子量が小さいヒアルロン酸および/またはその塩である。
本実施形態に係る製造方法は、陰イオン交換樹脂処理工程の後に、前記樹脂処理(陰イオン交換樹脂による処理)された前記加水分解物を噴霧乾燥または凍結乾燥させる工程を含む。
噴霧乾燥工程では、前記加水分解物を含む液を噴霧乾燥させて、固体のヒアルロン酸および/またはその塩の製造方法を得る。すなわち、前記噴霧乾燥工程により、分子量が3,500以下であり、2糖の割合が1質量%以上30質量%以下であり、塩素含量および硫黄含量がいずれも1質量%以下であり、かつ、かさ密度が0.25g/cm3よりも大きいヒアルロン酸および/またはその塩を得ることができる。
より具体的には、噴霧乾燥工程では、噴霧を適切に行うことができる点で、噴霧乾燥させる液は、加水分解物を8質量%以上35質量%以下含むことが好ましく、10質量%以上含むことがより好ましく、11質量%以上含むことがさらに好ましく、一方、30質量%以下であることが好ましく、28質量%以下含むことがより好ましく、26質量%以下含むことがさらに好ましく、24質量%以下含むことが特に好ましい。
噴霧乾燥工程では、市販の噴霧乾燥装置を用いて噴霧乾燥を行うことができる。市販の噴霧乾燥装置としては、ディスク型スプレードライヤーやベーン型スプレードライヤーが挙げられる。
噴霧乾燥工程では、ヒアルロン酸および/またはその塩の凍結および褐変を防止できる点で、噴霧乾燥工程におけるヒーター温度は通常200℃以下(好ましくは170℃以下)であることが好ましく、150℃以上(好ましくは100℃以上)であることがより好ましい。
より具体的には、凍結乾燥工程では、凍結を適切に行うことができる点で、凍結乾燥させる液は、加水分解物を8質量%以上35質量%以下含むことが好ましく、10質量%以上含むことがより好ましく、11質量%以上含むことがさらに好ましく、一方、28質量%以下含むことがより好ましく、26質量%以下含むことがさらに好ましく、24質量%以下含むことが特に好ましい。
凍結乾燥工程では、市販の凍結乾燥装置を用いて凍結乾燥を行うことができる。市販の凍結乾燥装置としては、アルバック社凍結乾燥機(DFR-5N-B)が挙げられる。
凍結乾燥工程では、ヒアルロン酸および/またはその塩の褐変を防止できる点で、凍結乾燥工程における温度は通常-20℃以下(好ましくは-30℃以下)であることが好ましく、-80℃以上(好ましくは-70℃以上)であることがより好ましい。
本実施形態に係る製造方法では、前記液相分解工程(第1低分子化工程)の前に、第2低分子化工程として、平均分子量が3,000以上50万以下の出発原料ヒアルロン酸および/またはその塩を酸性含水媒体(medium)中に分散させて、前記原料ヒアルロン酸および/またはその塩を得る工程(以下、「固相(solid phase)分解工程」ともいう。)をさらに含むことができる。
出発原料ヒアルロン酸および/またはその塩は、原料ヒアルロン酸および/またはその塩の出発原料であり、原料ヒアルロン酸および/またはその塩よりも平均分子量が大きい。
本実施形態に係る製造方法では、出発原料ヒアルロン酸および/またはその塩を分散させる酸性含水媒体に使用する溶媒としては、水溶性有機溶媒が挙げられる。水溶性有機溶媒としては、例えば、メタノール、エタノール、1-プロパノール、2-プロパノールなどのアルコール系溶媒(なかでも、低級アルコール)、アセトン、メチルエチルケトンなどのケトン系溶媒、テトラヒドロフラン、アセトニトリル等を挙げることができ、これらを単独でまたは組み合わせて使用することができる。
酸性含水媒体中において原料ヒアルロン酸および/またはその塩の溶解を防止し、収率低下を防ぐ点から、酸性含水媒体の全量に対する水の割合は40容量%以下が好ましく、30容量%以下がさらに好ましく、通常、1容量%以上である。
また、固相分解工程では、原料ヒアルロン酸および/またはその塩の褐変を防止し、かつ原料ヒアルロン酸および/またはその塩の低分子化を達成できる点で、前記酸性含水媒体のpHは1以下であることが好ましく、0以上であることがより好ましい。
なお、固相分解工程の代わりに、第2低分子化工程として、例えば、酵素分解、熱分解、原料ヒアルロン酸および/またはその塩が反応液に溶解した状態における酸分解、アルカリ分解、電子線照射による分解、および超音波による分解から選ばれる少なくとも1種の方法によって出発原料ヒアルロン酸および/またはその塩を低分子化して、原料ヒアルロン酸および/またはその塩を得ることができるが、最終的に得られるヒアルロン酸および/またはその塩における単糖、2糖、8糖の割合をコントロールしやすい点で、固相分解工程(すなわち、出発原料ヒアルロン酸および/またはその塩を酸性含水媒体に分散させ、該出発原料ヒアルロン酸および/またはその塩を固体状態で酸と反応させる方法)によって加水分解する方法が好ましい。
固相分解工程では、低分子化されたヒアルロン酸および/またはその塩の褐変を防ぐことができる点から、反応液の温度は通常95℃以下(好ましくは90℃以下)であることが好ましく、55℃以上(好ましくは60℃以上)であることがより好ましい。
固相分解工程では、低分子化されたヒアルロン酸および/またはその塩の褐変を防ぐことができる点から、反応時間は通常30分以上10時間以下であることが好ましく、60分以上2時間以下であることがより好ましい。
本実施形態に係る製造方法によれば、液相分解工程と、陰イオン交換樹脂処理工程と、噴霧乾燥工程または凍結乾燥工程と、を含むことにより、前記陰イオン交換樹脂処理工程で得られた液を使用して前記噴霧乾燥工程または凍結乾燥工程を行うことができるため、上記実施形態に係るヒアルロン酸および/またはその塩を固体として効率的に得ることができる。
(1)酵素を用いたヒアルロン酸および/またはその塩の低分子化方法と比較して、本実施形態に係る製造方法によれば、純度および白色度が高いヒアルロン酸および/またはその塩を得ることができ、抗原性をより低減することができ、かつ、製造コストを低減することができる。
本発明の一実施形態に係るヒアルロン酸および/またはその塩の製造方法は、平均分子量が3,500以下のヒアルロン酸および/またはその塩を8質量%以上35質量%以下含む液を噴霧乾燥または凍結乾燥させて、固体のヒアルロン酸および/またはその塩の製造方法を得る工程を含む。
本発明の一実施形態に係る食品は、上記実施形態に係るヒアルロン酸および/またはその塩を含む。より具体的には、本実施形態に係る食品は、上記実施形態に係るヒアルロン酸および/またはその塩を0.1質量%以上100質量%以下含有することができる。
本発明の一実施形態に係る化粧料は、上記実施形態に係るヒアルロン酸および/またはその塩を含む。
本発明の一実施形態に係る医薬品は、上記実施形態に係るヒアルロン酸および/またはその塩を含む。より具体的には、本実施形態に係る医薬品は、上記実施形態に係るヒアルロン酸および/またはその塩を5質量%以上100質量%以下含有することができる。
本発明の一実施形態に係るヒアルロン酸および/またはその塩は、平均分子量が3,500以下であり、かつ、以下の特徴(1)ないし(13)のうち1つまたはそれ以上(2個,3個,4個,5個,6個,7個,8個,9個,10個,11個,12個または13個)を有する。
(2)純度が90%以上である。
(3)色の色相を表すb値が10以下である。
(4)平均粒子径が10μm以上35μm以下である。
(5)粒子径の標準偏差が0.1以上0.3以下である。
(6)塩素含量が1質量%以下である。
(7)硫黄含量が1質量%以下である。
(8)2糖の割合が1質量%以上30質量%以下である。
(9)ヒアルロン酸分解酵素を含有しない。
(10)8糖の割合が1質量%以上30質量%以下である。
(11)2糖、4糖、6糖および8糖の合計が5質量%以上80質量%以下である。
(12)5質量%水溶液の動粘度が2.0mm2/s以下である。
(13)単糖の割合が3質量%以下である。
以下、実施例によって本発明をさらに詳細に説明するが、本発明は実施例に限定されない。
分子量1万の原料ヒアルロン酸約5kgをエタノール1kgで湿潤させ、攪拌機およびジャケットを装備した50L容タンクで2%塩酸25L(pH1.0、25kg)に添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、これを70℃で5時間保持し、加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水8Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:12質量%、ここで、ヒアルロン酸の濃度は、原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥(ヒーター温度:180℃)によって乾燥させ、白色微粉末のヒアルロン酸4.5kg(収率約90%)を得た。
HPLC分析装置:商品名「アライアンスPDAシステム」,日本ウォーターズ株式会社製
使用カラム:ゲル濾過カラム(商品名「Diol-120」,株式会社ワイエムシイ製
分析サンプル:ヒアルロン酸の0.1%(w/v)水溶液
カラム温度:40℃
流速:1mL/分
ヒアルロン酸の0.1%(w/v)水溶液の注入量:20μL
移動相:0.003Mリン酸バッファー(0.15M NaCl含有,pH7.0)
乾燥した分子量1万の原料ヒアルロン酸約2kgを攪拌機およびジャケットを装備した50L容タンクで2%塩酸25L(pH1.0、25kg)に添加し、原料ヒアルロン酸を約7質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、これを70℃で5時間保持し、加水分解を実施した(液相分解工程)。さらに、得られた加水分解物に25質量%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した上で陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水18Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。得られた溶液(ヒアルロン酸の濃度:4質量%、ここで、ヒアルロン酸の濃度は、原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥(ヒーター温度:180℃)によって乾燥したところ、霧状となり、ヒアルロン酸を回収することができなかった。
噴霧乾燥を行う代わりに凍結乾燥を行った以外は比較例1と同様にして、比較例2の白色微粉末のヒアルロン酸1.9kgを得た。
攪拌機およびジャケットを装備した200L容タンクに、8%塩酸28L(28kg)とエタノール100Lを満たし、攪拌しながら液温が70℃となるよう加熱した。70℃に達温後、攪拌しながら、平均分子量30万の出発原料ヒアルロン酸5kgをタンクに投入した。塩酸含有含水エタノール(pH0.2)の温度を70℃に維持するよう加熱を行ないながら、ヒアルロン酸微粉末が分散状態となるように攪拌し、攪拌を1時間行った(固相分解工程)。次いで、塩酸含有含水エタノールをデカンテーションにより除去した後、残存する固形物(エタノール1kgで湿潤した状態の原料ヒアルロン酸)約6kgに2%塩酸25L(pH1.0、25kg)を添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、70℃で5時間加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水12Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:11質量%、ここで、ヒアルロン酸の濃度は、出発原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥(ヒーター温度:180℃)によって乾燥させ、白色微粉末のヒアルロン酸4.5kg(収率約90%)を得た。なお、固相分解工程で得られた原料ヒアルロン酸の平均分子量を別途測定したところ約1万であった。
実施例2において主に、使用するタンクの容量、出発原料ヒアルロン酸の質量、塩酸の質量、エタノールの質量、水酸化ナトリウムの質量を全て100分の1に変更しスケールダウンし、噴霧乾燥する際のヒアルロン酸溶液の濃度を14質量%とした以外は、同様の方法で、実施例3のヒアルロン酸を得た。
実施例3において主に、樹脂を除去した後に得られた溶液に水を添加してヒアルロン酸の濃度を調整した以外は、同様の方法で、実施例4のヒアルロン酸11質量%を含む溶液を得た。この溶液を凍結乾燥させて、実施例4のヒアルロン酸を得た。
実施例2において主に、樹脂を除去した後に得られた溶液に水を添加してヒアルロン酸の濃度を調整した以外は、同様の方法で、比較例3のヒアルロン酸約1質量%(0.6質量%)を含む溶液を得た。この溶液を凍結乾燥させて、比較例3のヒアルロン酸を得た。
比較例3において主に、樹脂を除去した後に得られた溶液に添加する水の量を変更した他は比較例3と同様の方法にて、比較例4のヒアルロン酸6質量%を含む溶液を得た。この溶液を凍結乾燥させて、比較例4のヒアルロン酸を得た。
実施例2において主に、樹脂を除去した後に得られた溶液に添加する水の量を変更した他は比較例3と同様の方法にて、比較例5のヒアルロン酸6質量%を含む溶液を得た。この溶液を実施例2と同様の噴霧乾燥したところ、霧状となり、ヒアルロン酸を回収することができなかった。
2L容ビーカーに、8%塩酸280mL(280g)とエタノール1Lを満たし、攪拌しながら液温が70℃となるよう湯浴で加熱した。70℃に達温後、攪拌しながら、平均分子量30万の出発原料ヒアルロン酸50gをビーカーに投入した。塩酸含有含水エタノール(pH0.2)の温度を70℃に維持するよう加熱を行ないながら、ヒアルロン酸微粉末が分散状態となるように攪拌し、攪拌を1時間行った(固相分解工程)。次いで、塩酸含有含水エタノールをデカンテーションにより除去した後、残存する固形物を減圧乾燥により乾燥させた。乾燥後のヒアルロン酸約50gに2%塩酸150mL(pH1.0、150g)を添加したところヒアルロン酸がダマになり完全には溶解できなかったが、そのまま原料ヒアルロン酸を約25質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、70℃で5時間加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水120mLで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液20g添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:15質量%、ここで、ヒアルロン酸の濃度は、出発原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥によって乾燥させたところ、褐変したヒアルロン酸が得られ、得られたヒアルロン酸はb値が10以上であった。また、単糖の割合は4%であった。
実施例2において主に、固相分解工程の加水分解時間を2時間とし、陰イオン交換樹脂で処理をする前に、水酸化ナトリウムを添加して中和した後、エタノールを添加してヒアルロン酸を沈殿させ、比較例7のヒアルロン酸を得た。
攪拌機およびジャケットを装備した200L容タンクに、8%塩酸28L(28kg)とエタノール100Lを満たし、攪拌しながら液温が70℃となるよう加熱した。70℃に達温後、攪拌しながら、平均分子量30万の出発原料ヒアルロン酸5kgをタンクに投入した。塩酸含有含水エタノール(pH0.2)の温度を70℃に維持するよう加熱を行ないながら、ヒアルロン酸微粉末が分散状態となるように攪拌し、攪拌を1時間行った(固相分解工程)。次いで、塩酸含有含水エタノールをデカンテーションにより除去した後、残存する固形物(エタノール1kgで湿潤した状態の原料ヒアルロン酸)約6kgに2%塩酸25L(pH1.0、25kg)を添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、70℃で5時間加水分解を実施した(液相分解工程)。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:15質量%、ここで、ヒアルロン酸の濃度は、出発原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥によって乾燥させ、白色微粉末のヒアルロン酸4.5kg(収率約90%)を得た。なお、固相分解工程で得られた原料ヒアルロン酸の平均分子量を別途測定したところ約1万であった。
攪拌機およびジャケットを装備した200L容タンクに、8%塩酸14L(14kg)とエタノール53Lを満たし、攪拌しながら液温が70℃となるよう加熱した。70℃に達温後、攪拌しながら、平均分子量30万の出発原料ヒアルロン酸5kgをタンクに投入した。塩酸含有含水エタノール(pH0.2)の温度を70℃に維持するよう加熱を行ないながら、ヒアルロン酸微粉末が分散状態となるように攪拌し、攪拌を1時間行った(固相分解工程)。次いで、塩酸含有含水エタノールをデカンテーションにより除去した後、残存する固形物(エタノール1.5kgで湿潤した状態の原料ヒアルロン酸)約6.5kgに2%塩酸25L(pH1.0、25kg)を添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、70℃で3時間加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水8Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:12質量%、ここで、ヒアルロン酸の濃度は、出発原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を凍結乾燥によって乾燥させ、白色微粉末のヒアルロン酸4.5kg(収率約90%)を得た。なお、固相分解工程で得られた原料ヒアルロン酸の平均分子量を別途測定したところ約1万であった。
攪拌機およびジャケットを装備した200L容タンクに、8%塩酸14L(14kg)とエタノール53Lを満たし、攪拌しながら液温が70℃となるよう加熱した。70℃に達温後、攪拌しながら、平均分子量30万の出発原料ヒアルロン酸5kgをタンクに投入した。塩酸含有含水エタノール(pH0.2)の温度を70℃に維持するよう加熱を行ないながら、ヒアルロン酸微粉末が分散状態となるように攪拌し、攪拌を1時間行った(固相分解工程)。次いで、塩酸含有含水エタノールをデカンテーションにより除去した後、残存する固形物(エタノール1.5kgで湿潤した状態の原料ヒアルロン酸)約6.5kgに2%塩酸25L(pH1.0、25kg)を添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、70℃で6時間加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)を行い、水8Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:12質量%、ここで、ヒアルロン酸の濃度は、出発原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を凍結乾燥によって乾燥させ、白色微粉末のヒアルロン酸4.5kg(収率約90%)を得た。なお、固相分解工程で得られた原料ヒアルロン酸の平均分子量を別途測定したところ約1万であった。
実施例3において主に、樹脂を除去した後に得られた溶液を水押し希釈せずにそのまま用いた以外は、同様の方法で、実施例7のヒアルロン酸22質量%を含む溶液を得た。この溶液を噴霧乾燥させて、実施例7のヒアルロン酸を得た。
実施例7において、固相分解工程において使用したエタノールをメタノールに置き換えた以外は同様の方法で、実施例8のヒアルロン酸22質量%を含む溶液を得た。この溶液を噴霧乾燥させて、実施例8のヒアルロン酸を得た。
分子量11万の原料ヒアルロン酸約5kgをエタノール1kgで湿潤させ、攪拌機およびジャケットを装備した50L容タンクで2%塩酸25L(pH1.0、25kg)に添加し、原料ヒアルロン酸を約16質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製しようとしたところ、ヒアルロン酸溶液が非常に高粘度となり、攪拌することができなかった。
分子量11万の原料ヒアルロン酸約0.2kgをエタノール0.05kgで湿潤させ、攪拌機およびジャケットを装備した50L容タンクで2%塩酸25L(pH1.0、25kg)に添加し、原料ヒアルロン酸を約0.8質量%含む酸性原料ヒアルロン酸水溶液(pH約1)を調製し、これを70℃で10時間保持し、加水分解を実施した(液相分解工程)。さらに、得られた加水分解物を含む液を陰イオン交換樹脂処理(商品名:ダイヤイオンもしくはセパビーズ、三菱化学製)し、水8Lで押し出すとともに希釈し、80メッシュフィルターによって樹脂を除去した。25%水酸化ナトリウム水溶液2kg添加し、pHを4.0以上6.5以下に調製した。得られた溶液(ヒアルロン酸の濃度:約0.6質量%、ここで、ヒアルロン酸の濃度は、原料ヒアルロン酸の添加量をヒアルロン酸の含有量とみなして算出した。)を噴霧乾燥(ヒーター温度:180℃)によって乾燥させたとろ、霧状となり、ヒアルロン酸を回収することができなかった。
本配合例では、以下に記す処方にて、実施例1で得られたヒアルロン酸を配合した美容液(美白保湿エッセンス)を調製した。本配合例で使用した、実施例1で得られたヒアルロン酸は適度な結着性を有し、粉が舞いにくく本配合例では製剤化が容易であった。
ヒアルロン酸(実施例1) 1.0%
加水分解ヒアルロン酸 0.1%
1,3-ブチレングリコール 5.0%
グリセリン 1.5%
POEソルビタンモノステアリン酸エステル 1.0%
ソルビタンモノステアリン酸エステル 0.5%
キサンタンガム 0.2%
アルギン酸ナトリウム 0.2%
カルボキシビニルポリマー 0.2%
水酸化カリウム 0.1%
オリーブ油 0.2%
トコフェロール 0.1%
EDTA-2ナトリウム 0.02%
アルギニン 0.15%
グリチルリチン酸ジカリウム 0.05%
アルブチン 0.2%
パルミチン酸レチノール 0.2%
クジンエキス 0.2%
海藻エキス 0.2%
トラネキサム酸 0.1%
エラスチン 0.1%
コラーゲン 0.1%
リン酸アスコルビン酸マグネシウム 0.1%
クエン酸ナトリウム 1.0%
クエン酸 0.1%
プロピルパラベン 0.1%
メチルパラベン 0.15%
香料 適量
精製水 残量
本配合例では、以下に記す処方にて、実施例1で得られたヒアルロン酸を配合したソフトカプセルを調製した。本配合例で使用した、実施例1で得られたヒアルロン酸は適度な結着性を有し、カプセルへの充填率が高く、本配合例では製剤化が容易であった。
ヒアルロン酸(実施例1) 20%
オリーブ油 35%
ミツロウ 5%
中鎖脂肪酸トリグリセリド 5%
ゼラチン 25%
グリセリン 10%
本配合例では、以下に記す処方にて、実施例1で得られたヒアルロン酸を配合した散剤(顆粒剤)を調製した。本配合例で使用した、実施例1で得られたヒアルロン酸は適度な結着性を有し、粉が舞いにくく本配合例では製剤化が容易であった。
ヒアルロン酸(実施例1) 10%
乳糖 60%
トウモロコシデンプン 25%
ヒプロメロース 5%
本配合例では、以下に記す処方にて、実施例1で得られたヒアルロン酸を配合した錠剤を調製した。本配合例で使用した、実施例1で得られたヒアルロン酸は適度な結着性を有し、打錠適性に優れているため、本配合例では製剤化が容易であった。
ヒアルロン酸(実施例1) 25%
乳糖 24%
結晶セルロース 20%
トウモロコシデンプン 15%
デキストリン 15%
二酸化ケイ素 1%
本配合例では、以下に記す処方にて、実施例1で得られたヒアルロン酸を配合したスパウトパウチ入り白桃ゼリー飲料を調製した。本配合例で使用した、実施例1で得られたヒアルロン酸は適度な結着性を有し、粉が舞いにくく本配合例では調製が容易であった。
ヒアルロン酸(実施例1) 0.20%
キサンタンガム 1.00%
カラギーナン 0.5%
デキストリンアルコール 3.0%
スクラロース 1%
4倍濃縮白桃果汁 5.00%
クエン酸 0.60%
クエン酸ナトリウム 0.20%
L-アスコルビン酸 0.10%
ピーチ香料 0.20%
精製水 残量
Claims (8)
- 平均分子量が3,500以下であり、2糖の割合が1質量%以上30質量%以下であり、塩素含量および硫黄含量がいずれも1質量%以下であり、かつ、かさ密度が0.25g/cm3よりも大きい、ヒアルロン酸および/またはその塩。
- 請求項1において、
平均粒子径が10μm以上35μm以下である、ヒアルロン酸および/またはその塩。 - 請求項1または2において、
粒子径の標準偏差が0.1以上0.3以下である、ヒアルロン酸および/またはその塩。 - 低級アルコールと、平均分子量が3,500以上10万以下の原料ヒアルロン酸および/またはその塩と、酸と、を含む酸性原料ヒアルロン酸溶液を調製する工程と、
前記調製する工程で得られた前記酸性原料ヒアルロン酸溶液中で前記原料ヒアルロン酸および/またはその塩を酸加水分解する工程と、
前記酸加水分解により得られた加水分解物を含む酸性溶液を陰イオン交換樹脂で処理する工程と、
前記樹脂処理された前記加水分解物を噴霧乾燥または凍結乾燥させる工程と、を含み、
前記酸性原料ヒアルロン酸溶液は、15質量%以上35質量%以下の前記原料ヒアルロン酸および/またはその塩を含み、かつ、
前記酸性原料ヒアルロン酸溶液は、前記原料ヒアルロン酸および/またはその塩100質量部に対して、5質量部以上60質量部以下の前記低級アルコールを含む、ヒアルロン酸および/またはその塩の製造方法。 - 請求項4において、
前記噴霧乾燥させる工程は、前記加水分解物を含む液を噴霧乾燥する工程を含み、
前記加水分解物を含む液の質量に対する前記加水分解物の質量が8質量%以上35質量%以下である、ヒアルロン酸および/またはその塩の製造方法。 - 請求項1ないし3のいずれか1項に記載のヒアルロン酸および/またはその塩を含む、食品。
- 請求項1ないし3のいずれか1項に記載のヒアルロン酸および/またはその塩を含む、化粧料。
- 請求項1ないし3のいずれか1項に記載のヒアルロン酸および/またはその塩を含む、医薬品。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580004371.XA CN105899544B (zh) | 2014-01-14 | 2015-01-13 | 透明质酸和/或其盐及其制造方法、以及包含该透明质酸和/或其盐的食品、化妆品和药品 |
EP15737598.1A EP3103815B1 (en) | 2014-01-14 | 2015-01-13 | Hyaluronic acid and/or salt thereof, method for producing same, and food, cosmetic, and pharmaceutical containing said hyaluronic acid and/or salt thereof |
JP2015527613A JP5824599B1 (ja) | 2014-01-14 | 2015-01-13 | ヒアルロン酸および/またはその塩の製造方法 |
KR1020167019088A KR102301455B1 (ko) | 2014-01-14 | 2015-01-13 | 히알루론산 및/또는 그 염 및 그 제조 방법, 그리고, 그 히알루론산 및/또는 그 염을 포함하는 식품, 화장료, 및 의약품 |
US15/110,909 US20160333119A1 (en) | 2014-01-14 | 2015-01-13 | Hyaluronic acid and/or salt thereof, method for producing same, and food, cosmetic, and pharmaceutical containing said hyaluronic acid and/or salt thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-004677 | 2014-01-14 | ||
JP2014004677 | 2014-01-14 | ||
JP2014-080566 | 2014-04-09 | ||
JP2014080566 | 2014-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015108029A1 true WO2015108029A1 (ja) | 2015-07-23 |
Family
ID=53542918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/050638 WO2015108029A1 (ja) | 2014-01-14 | 2015-01-13 | ヒアルロン酸および/またはその塩およびその製造方法、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160333119A1 (ja) |
EP (1) | EP3103815B1 (ja) |
JP (1) | JP5824599B1 (ja) |
KR (1) | KR102301455B1 (ja) |
CN (1) | CN105899544B (ja) |
TW (1) | TWI653987B (ja) |
WO (1) | WO2015108029A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017048306A (ja) * | 2015-09-01 | 2017-03-09 | イビデン株式会社 | ヒアルロン酸及び/又はその塩の粉末 |
WO2019082922A1 (ja) * | 2017-10-27 | 2019-05-02 | 大日精化工業株式会社 | 化粧料用成形物及びその製造方法 |
JP2019104937A (ja) * | 2019-04-04 | 2019-06-27 | イビデン株式会社 | ヒアルロン酸及び/又はその塩の粉末 |
KR20220126348A (ko) * | 2021-03-09 | 2022-09-16 | (주) 미영씨앤씨 | 초 저분자 히알루론산을 포함하는 히알루론산 올리고머 제조방법 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6599673B2 (ja) * | 2015-07-17 | 2019-10-30 | キユーピー株式会社 | ヒアルロン酸および/またはその塩、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
WO2017192052A1 (en) * | 2016-05-02 | 2017-11-09 | Subasinghe Nissanke George Premalal Jayantha Dias | Treatment of keratin-containing biological materials |
CN109206537B (zh) * | 2018-10-10 | 2021-04-09 | 华熙生物科技股份有限公司 | 一种乙酰化透明质酸钠的制备方法及其应用 |
CN110946825B (zh) * | 2019-10-24 | 2022-04-15 | 山东福瑞达生物股份有限公司 | 一种盐水鼻腔护理液 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62289197A (ja) * | 1986-06-06 | 1987-12-16 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸ナトリウム粉末の製造法 |
JPH02142801A (ja) * | 1988-11-25 | 1990-05-31 | Chisso Corp | 粉末状のヒアルロン酸ナトリウムの製造方法 |
JP2006265287A (ja) | 2005-03-22 | 2006-10-05 | Q P Corp | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
WO2008004530A1 (fr) * | 2006-07-03 | 2008-01-10 | Kyowa Hakko Bio Co., Ltd. | Poudre d'acide hyaluronique et sel de celui-ci, et son procédé de production |
JP2009155486A (ja) | 2007-12-27 | 2009-07-16 | Kikkoman Corp | 低分子化ヒアルロン酸とその製造法 |
WO2011070948A1 (ja) * | 2009-12-08 | 2011-06-16 | キユーピー株式会社 | 精製ヒアルロン酸類の製造方法 |
JP2012001696A (ja) * | 2010-06-21 | 2012-01-05 | Toshitsu Kagaku Kenkyusho:Kk | 低分子ヒアルロン酸の製造方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60251898A (ja) * | 1984-05-25 | 1985-12-12 | Shiseido Co Ltd | 醗酵法によるヒアルロン酸の製造方法 |
JP5026266B2 (ja) * | 2004-08-12 | 2012-09-12 | リポクセン テクノロジーズ リミテッド | 分別 |
WO2007099830A1 (ja) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | 新規な低分子ヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物 |
CN101429255A (zh) * | 2008-10-24 | 2009-05-13 | 山东福瑞达生物化工有限公司 | 一种低分子透明质酸钠的制备方法 |
KR101627014B1 (ko) * | 2010-03-17 | 2016-06-03 | 덴카 주식회사 | 히알루론산의 정제 방법 |
CN102304193A (zh) * | 2011-09-29 | 2012-01-04 | 胡如桂 | 一种寡聚透明质酸的制备方法及其用途 |
JP5723919B2 (ja) * | 2013-04-22 | 2015-05-27 | キユーピー株式会社 | 新規なヒアルロン酸および/またはその塩の製造方法、ならびに該ヒアルロン酸および/またはその塩を含有する食品組成物、経口用皮膚改善剤または経口用皮膚含水量増加剤の製造方法 |
-
2015
- 2015-01-13 WO PCT/JP2015/050638 patent/WO2015108029A1/ja active Application Filing
- 2015-01-13 US US15/110,909 patent/US20160333119A1/en not_active Abandoned
- 2015-01-13 CN CN201580004371.XA patent/CN105899544B/zh active Active
- 2015-01-13 KR KR1020167019088A patent/KR102301455B1/ko active IP Right Grant
- 2015-01-13 JP JP2015527613A patent/JP5824599B1/ja active Active
- 2015-01-13 EP EP15737598.1A patent/EP3103815B1/en active Active
- 2015-01-14 TW TW104101180A patent/TWI653987B/zh active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62289197A (ja) * | 1986-06-06 | 1987-12-16 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸ナトリウム粉末の製造法 |
JPH02142801A (ja) * | 1988-11-25 | 1990-05-31 | Chisso Corp | 粉末状のヒアルロン酸ナトリウムの製造方法 |
JP2006265287A (ja) | 2005-03-22 | 2006-10-05 | Q P Corp | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
WO2008004530A1 (fr) * | 2006-07-03 | 2008-01-10 | Kyowa Hakko Bio Co., Ltd. | Poudre d'acide hyaluronique et sel de celui-ci, et son procédé de production |
JP2009155486A (ja) | 2007-12-27 | 2009-07-16 | Kikkoman Corp | 低分子化ヒアルロン酸とその製造法 |
WO2011070948A1 (ja) * | 2009-12-08 | 2011-06-16 | キユーピー株式会社 | 精製ヒアルロン酸類の製造方法 |
JP2012001696A (ja) * | 2010-06-21 | 2012-01-05 | Toshitsu Kagaku Kenkyusho:Kk | 低分子ヒアルロン酸の製造方法 |
Non-Patent Citations (2)
Title |
---|
CHIKAKO YOMOTA: "Evaluation of Molecular Weights of Sodium Hyaluronate Preparations by SEC-MALLS", BULL. NATL. INST. HEALTH SCI., vol. 121, 2003, pages 030 - 033 |
TORVARD C LAURENT; MARION RYAN; ADOLPH PIETRUS ZKIEWICZ: "Fractionation of hyaluronic Acid", BIOCHEMINA ET BIOPHYSICA ACTA., vol. 42, 1960, pages 476 - 485, XP023382851, DOI: doi:10.1016/0006-3002(60)90826-X |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017048306A (ja) * | 2015-09-01 | 2017-03-09 | イビデン株式会社 | ヒアルロン酸及び/又はその塩の粉末 |
WO2019082922A1 (ja) * | 2017-10-27 | 2019-05-02 | 大日精化工業株式会社 | 化粧料用成形物及びその製造方法 |
JP2019077665A (ja) * | 2017-10-27 | 2019-05-23 | 大日精化工業株式会社 | 化粧料用成形物及びその製造方法 |
AU2018357134B2 (en) * | 2017-10-27 | 2021-11-04 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Cosmetic molded article and method for manufacturing same |
RU2759768C1 (ru) * | 2017-10-27 | 2021-11-17 | Дайнитисейка Колор Энд Кемикалз Мфг. Ко., Лтд. | Косметическое формованное изделие и способ его изготовления |
US11458088B2 (en) | 2017-10-27 | 2022-10-04 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Cosmetic molded article and method for manufacturing same |
JP2019104937A (ja) * | 2019-04-04 | 2019-06-27 | イビデン株式会社 | ヒアルロン酸及び/又はその塩の粉末 |
KR20220126348A (ko) * | 2021-03-09 | 2022-09-16 | (주) 미영씨앤씨 | 초 저분자 히알루론산을 포함하는 히알루론산 올리고머 제조방법 |
KR102548168B1 (ko) | 2021-03-09 | 2023-06-27 | (주) 미영씨앤씨 | 초 저분자 히알루론산을 포함하는 히알루론산 올리고머 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
CN105899544B (zh) | 2019-09-20 |
JPWO2015108029A1 (ja) | 2017-03-23 |
KR20160106076A (ko) | 2016-09-09 |
US20160333119A1 (en) | 2016-11-17 |
EP3103815B1 (en) | 2018-12-19 |
JP5824599B1 (ja) | 2015-11-25 |
KR102301455B1 (ko) | 2021-09-10 |
TWI653987B (zh) | 2019-03-21 |
TW201611819A (en) | 2016-04-01 |
EP3103815A4 (en) | 2017-07-12 |
CN105899544A (zh) | 2016-08-24 |
EP3103815A1 (en) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5824599B1 (ja) | ヒアルロン酸および/またはその塩の製造方法 | |
JP6377020B2 (ja) | カルボキシメチル基含有修飾ヒアルロン酸および/またはその塩、ならびにこれを含む化粧料、食品組成物および医薬組成物 | |
KR102091794B1 (ko) | 분산액 및 하이드로겔 형성방법 | |
JP4845071B2 (ja) | 修飾ヒアルロン酸および/またはその塩、ならびにその製造方法およびこれを含む化粧料 | |
JP5852560B2 (ja) | ヒアルロン酸金属塩の製造方法、ヒアルロン酸金属塩を含む化粧品の製造方法、ならびにヒアルロン酸亜鉛およびその製造方法 | |
JP2013181001A (ja) | ヒアルロン酸組成物、およびこれを含む皮膚外用剤 | |
JP6613300B2 (ja) | ヒアルロン酸誘導体およびその製造方法、ならびにヒアルロン酸誘導体を含む化粧料、食品組成物および医薬組成物 | |
JP2008285421A (ja) | 毛髪改質浸透剤およびこれを用いた毛髪用化粧料 | |
WO2015053282A1 (ja) | カルボキシメチル基含有修飾ヒアルロン酸および/またはその塩の架橋物およびその製造方法 | |
JP5814181B2 (ja) | 皮膚バリア機能改善剤 | |
JP6599673B2 (ja) | ヒアルロン酸および/またはその塩、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 | |
JP5734536B1 (ja) | カルボキシメチル基含有修飾ヒアルロン酸および/またはその塩の架橋物およびその製造方法 | |
JP2016104710A (ja) | 錠剤またはカプセル成形物 | |
JP5683410B2 (ja) | 化粧料 | |
JP2004107242A (ja) | 乾燥肌改善用キット | |
JP2004107238A (ja) | 乾燥肌改善用キット | |
JP5849017B2 (ja) | 化粧料及びその製造方法 | |
JP2004059473A (ja) | 化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2015527613 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15737598 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15110909 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20167019088 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015737598 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015737598 Country of ref document: EP |